延胡索提取物治疗冠心病室性心律失常的机理研究
|
摘要
1.研究目的
1.1系统评价分析中医药治疗冠心病室性早搏的安全性及有效性,为中医药治疗冠心病室性早搏提供循证医学证据。
1.2通过对“冠心病临床科研一体化技术平台”数据库的挖掘分析,研究冠心病室性心律失常的证治规律,探索治疗冠心病室性心律失常的遣方用药特点。
1.3从蛋白组学、酶学、免疫组化形态学方面探索延胡索提取物干预大鼠急性心肌梗死后室性心律失常的作用机制,为延胡索提取物治疗冠心病室性心律失常提供实验依据,为延胡索提取物新药的开发奠定基础。
2.方法
2.1系统评价方法
计算机检索PubMed.中国生物医学文献数据库(web版)、中文生物医学期刊数据库(web版)CMCC,VIP中文科技期刊数据库(Web版),CNKI中国期刊全文数据库(Web版),万方数据库,检索至2011年2月各资料库所有可得文献。采用Cochrane协作网提供的Revman5.1.4(Review Manager5.1.4)软件分析中医药治疗冠心病室性早搏的疗效,根据改良Jadad评分对研究的质量进行评价。
2.2数据挖掘方法
利用SQL Server 2000工具对人口学资料、一般临床特点、证候、治法及方药数据进行转换、加载,利用Business Objects软件进行冠心病室性心律失常临床需求的多维主题查询及Web多维分析；利用Oracle 10g实现冠心病室性心律失常证候分布、遣方用药规律的挖掘分析。利用冠心病临床科研一体化技术平台对室性心律失常的中药配伍规律,药物与证候之间的关系进行复杂网络分析。
2.3延胡索提取物治疗大鼠急性心肌梗死后室性心律失常的实验研究方法
建立大鼠急性心肌梗死模型,将wistar大鼠随机分为正常组、假手术组、模型组、美托洛尔组、参松养心胶囊组、延胡索提取物高、中、低剂量组。N-BT染色测量心肌梗死面积,ELASA法测定Na+-K+-ATPase和Ca2+-ATPase活性,免疫蛋白印迹法测定缝隙连接蛋白43(Connexin 43,CX43)及其磷酸化CX43 (Phospyo-CX43, P-CX43)的蛋白含量,及免疫组化法观察CX43及P-CX43的表达位置。从以上几个方面来探讨延胡索提取物对大鼠急性心肌梗死后室性心律失常的作用机制。
3.结果
3.1系统评价结果--中医药治疗冠心病室性早搏的Meta分析
与空白对照或西药对照相比,中医药可有效治疗冠心病室性早搏,减少冠心病室性早搏次数,差异有统计学意义(p<0.05)。Jadad评分表明研究质量大部分属于低质量。
3.2数据挖掘结果
入选了386例冠心病室性心律失常患者,男性201例,女性185例,平均年龄70.06±10.33岁。合并病及疾病亚型主要是高血压、心功能不全、心绞痛、陈旧心肌梗死、糖尿病。冠心病室性心律失常的主要证候为血瘀、气虚、痰浊。患者首次使用的中药主要是茯苓、丹参、当归、半夏、麦冬、甘草、红花、川芎、桃仁、陈皮,首次使用的中药主要为补气药、活血调经药、理气药。最常使用的抗心律失常药为美托洛尔、胺碘酮与慢心律。室性心律失常患者预后在冠心病心律失常患者中较差、无效与死亡率明显高于其他类型心律失常患者。冠心病室性心律失常药物-证候复杂网络挖掘分析显示,常见证候为气虚、血瘀、痰浊,与证候对应的药物主要是丹参、茯苓、当归、麦冬、赤芍、红花、川芎、甘草、半夏、桃仁、陈皮、五味子。
3.3延胡索提取物治疗大鼠急性心肌梗死后室性心律失常的实验研究结果
3.3.1心梗面积
在梗死区面积与梗死区面积／心室总面积上,延胡索提取物小、中剂量组及美托洛尔、参松养心胶囊治疗组均有缩小急性心肌梗死面积的作用(P<0.05)。
3.3.2 Na+-K+-ATPase与Ca2+-ATPase活性结果
与正常组比较,模型组的Na+-K+-ATPase与Ca2+-ATPase活性明显降低(P<0.01)。延胡索碱提取物组与其他药物治疗组均可以明显提高大鼠急性心肌梗死后降低的Na+-K+-ATPase与Ca2+-ATPase活性(P<0.01)。
3.3.3 CX43与P-CX43免疫蛋白印迹结果
与正常组比较,模型组的CX43及P-CX43蛋白含量明显减少(P<0.05)。延胡索提取物小、中剂量组及美托洛尔、参松养心胶囊组均能提高急性心肌梗死后降低的CX43与P-CX43的蛋白含量(P<0.05)。其中延胡索提取物中剂量组与美托洛尔组疗效相当。
3.3.4各组大鼠心脏大体病理形态学结果
HE染色结果显示,延胡索提取物治疗组及其他药物治疗组,肌纤维损伤程度减轻,大部分肌纤维完整,排列整齐,仅见局灶性纤维组织增生,淋巴细胞浸润,而模型组心肌纤维排列紊乱,部分胞浆溶解,纤维组织增生明显,伴玻璃样变,可见肉芽组织形成及坏死组织。
3.3.5 CX43与P-CX43免疫组化结果
正常组CX43与P-CX43主要分布在细胞端端连接处,即闰盘区域。而模型组,细胞结构被破坏,CX43与P-CX43表达明显降低,且出现侧边化现象明显。延胡索提取物治疗组与美托洛尔组、参松养心胶囊组,CX43与P-CX43表达较模型组明显增加,细胞结构损伤较模型组小,亦有侧边化现象。
4.结论
4.1系统评价提示中医药对冠心病室性早搏有一定的疗效及安全性,但因纳入研究质量较低,需更多高质量研究进一步验证。
4.2冠心病室性心律失常的主要证候为血瘀、气虚、痰浊,常用中药为丹参、茯苓、当归、麦冬、赤芍、红花、川芎、甘草、半夏、桃仁、陈皮、五味子,与证候相应的中药主要为补气药、活血调经药、理气药等。
4.3延胡索提取物能减少大鼠急性心肌梗死面积,改善心肌缺血损伤,提高梗死后心肌的Na+-K+-ATPase与Ca2+-ATPase活性和梗死后减少的CX43与P-CX43的蛋白含量,减少CX43与P-CX43侧边化现象,从而降低室性心律失常的发生。
1.1 To systematically review the effect and safety of Chinese medical treatment of coronary heart disease (CHD) patients with ventricular premature complexes (VPC), so as to provide evidence for Chinese medicine treating CHD patients with VPC.
1.2 Using the data mining technology to dig the data base "CHD platform of integrated clinical and scientific research", to investigate diagnose and treatment regularity of Chinese medicine treating CHD patients with VPC, and to explore the prescription and medication features.
1.3 From the aspects of proteomics, enzymology and immunohistochemical morphology, to explore the mechanism of Yanhusuo extract (YE) on rat model of ventricular arrhythmia (VA) after acute myocardial infarction (AMI), so as to provide experimental evidences for YE preventing ventricular arrhythmia from CHD, especially from AMI, and settle the foundation to explore the new medicine of YE.
2. Methods
2.1 Methods of systemic review
Databases of PubMed, CBM, CMCC, VIP, CNKI and WanFang were searched for all available data till February 2011. RevMan5.1.4 software was used to conduct meta-analysis. Jadad score was used to assess the quality of the included trials.
2.2 Methods of data mining
The data change-over and data loading for demography information general clinical characteristic、syndromes、therapeutic methods and Chinese medicine prescription were managed by SQL Server 2000 software. Multi-subject inquest and web analysis for the request of clinical need of VA in CHD were managed by Business Objects software. The syndromes distribution and TCM prescription of VA in CHD were dug and analyzed by Oracle 10g software. The Chinese medicine compatibility regularity and the relationship between Chinese medicine and syndromes were explored by complex networks analysis.
2.3 Methods of experimental research for YE treating VA after AMI in rats
To establish rat model of AMI, Wistar rats were randomly divided into normal group, sham group, model group, metoprolol group, Shensong Yangxin Capsule (SYC) group and low dosage、median dosagee and high dosage of YE groups. The infarction area was measured by N-BT staining. The Na+-K+-ATPase and Ca2+-ATPase activities were measured by ELASA method. Western Blot method was used to measure the protein levels of connexin43 (CX43) and phosphor-CX43 (P-CX43), and immnohistochemical method was used to observe the expression location of CX43 and P-CX43. From above all aspects to explore the mechanism of YE on rat VA model after AMI.
3. Results
3.1 Results of systematic review---the effect of Chinese medicine on CHD patients with VPC, a meta-analysis.
Compared with blank control group or western medicine group, Chinese medicine might treat CHD patients with VPC effectively, and also might reduce the VPC frequency (P<0.05). According to Jadad score, the quality of most of the trials was low.
3.2 Results of data mining analysis
386 CHD patients with VA aged 70.06±10.33 years in average were enrolled, including 201 males and 185 females. The subtypes and combined diseases were hypertension, heart failure, angina pectoris, old myocardial infarction,and diabetes mellitus. The main syndromes of CHD patients with VA were blood stasis, qi deficiency and phlegm-turbid. The first TCM prescription after admission mainly contained Fuling, Danshen, Danggui, Banxia, Maidong, Gancao, Honghua, Chuanxiong, Taoren, and Chenpi. The main functions of these Chinese medicines above were tonifying qi, activating blood and regulating qi. The main anti-arrhythmia medicines were metoprolol, amiodarone and mexiletine. The prognosis of CHD patients with VA was worse than the other types of CHD patients with arrhythmia, the ineffective ratio and mortality were much higher. The complex netmork analysis of medicine-syndrome showed that the main syndromes of CHD patients were qi deficiency, blood stasis and phlegm-turbid. The corresponded medicines for treating the main syndromes were Danshen, Fuling, Danggui, Maidong, Chishao, Honghua, Chuanxiong, Gancao, Banxia, Taoren, Chenpi and Wuweizi.
3.3 Results of experimental research into YE treating VA after AMI in rats
3.3.1 Result of myocardial infarction area
Compared with the model group, low dosage and median dosage group of Yanhusuo Extract, Metoprolol group and Shensong Yangxin Capsule group could reduce the myocardial infarction area and lower the ratio of myocardial infarction area/ventricle area (P<0.05).
3.3.2 Result of Na+-K+-ATPase and Ca2+-ATPase activities
Compared with the normal group, both the Na+-K+-ATPase and Ca2+-ATPase activities in model group were lowered obviously (P<0.01). The low、median、high dosage of YE and other medicine groups could improve the level of Na+-K+-ATPase and Ca2+-ATPase activities, compared with model group (P<0.01).
3.3.3 Result of protein level of CX43 and P-CX43 using Western Blot method.
Compared with normal group, the protein levels of CX43 and P-CX43 in model group were obviously lowered (P<0.05). Except the high dosage of YE group, the other medical groups could improve the reduced protein levels of CX43 and P-CX43 after AMI (P<0.05). In addition, the effect of median dosage of YE group was as good as Metoprolol group.
3.3.4 Result of pathomorphology in general of the rat hearts in all the groups
Hematoxylin and Eosin (HE) staining showed that the low、median、high dosage of YE and other medicine groups could relieve the muscle fiber injury. Most of muscle fibers in the rat hearts of these groups were intact and line up in order. Only local fibroplasias and lymphocytes infiltrating were seen. Nevertheless, in the model group, cardiac muscle fibers lined up disorderly. Plasmolysis, fibroplasias, glassy degeneration, granulation tissue and necrotic tissue were seen.
3.3.5 Result of immunohistochemical CX43 and P-CX43
In the normal group, CX43 and P-CX43 were mainly located at end-to-end apposition, also known as the myocardial cell intercalated disc region. In the model group, cellular structure was destroyed; CX43 and P-CX43 expression decreased obviously, and dislocated from end-to-end to side-to-side connections, also called lateralization. Compared with model group, the expression of CX43 and P-CX43 in YE groups, Metoprolol group and Shensong Yangxin Capsule group increased obviously, and just some of the cellular structures suffered from injury. However, some cardiocytes appeared lateralization.
4. Conclusion
4.1 The result of systematic review suggested that Chinese medicine could treat CHD patients with VPC effectively and safely. However, much more high quality researches are still needed to back up this result.
4.2 Blood stasis, qi deficiency and phlegm-turbid were the main syndrome elements of CHD patients with VA. The most of Chinese medicine used were Danshen, Fuling, Danggui, Chishao, Honghua, Chuanxiong, Gancao, Banxia, Taoren, Chenpi, and Wuweizi. Corresponded with the main syndrome, the functions of these Chinese medicines were tonifying qi, activating blood and regulating qi.
4.3 Yanhuosuo Extract could reduce the acute myocardial infarction area on rat AMI model, enhance the protective effect of ischemia injury, increase the activities of Na+-K+-ATPase and Ca2+-ATPase and the reduced protein level of CX43 and P-CX43 after AMI, and reduce the lateralization of CX43 and P-CX43, and accordingly reduce the genesis of ventricular arrhythmia. The mechanism of YE treating ventricular arrhythmia might be related to above all.
1.1系统评价分析中医药治疗冠心病室性早搏的安全性及有效性,为中医药治疗冠心病室性早搏提供循证医学证据。
1.2通过对“冠心病临床科研一体化技术平台”数据库的挖掘分析,研究冠心病室性心律失常的证治规律,探索治疗冠心病室性心律失常的遣方用药特点。
1.3从蛋白组学、酶学、免疫组化形态学方面探索延胡索提取物干预大鼠急性心肌梗死后室性心律失常的作用机制,为延胡索提取物治疗冠心病室性心律失常提供实验依据,为延胡索提取物新药的开发奠定基础。
2.方法
2.1系统评价方法
计算机检索PubMed.中国生物医学文献数据库(web版)、中文生物医学期刊数据库(web版)CMCC,VIP中文科技期刊数据库(Web版),CNKI中国期刊全文数据库(Web版),万方数据库,检索至2011年2月各资料库所有可得文献。采用Cochrane协作网提供的Revman5.1.4(Review Manager5.1.4)软件分析中医药治疗冠心病室性早搏的疗效,根据改良Jadad评分对研究的质量进行评价。
2.2数据挖掘方法
利用SQL Server 2000工具对人口学资料、一般临床特点、证候、治法及方药数据进行转换、加载,利用Business Objects软件进行冠心病室性心律失常临床需求的多维主题查询及Web多维分析；利用Oracle 10g实现冠心病室性心律失常证候分布、遣方用药规律的挖掘分析。利用冠心病临床科研一体化技术平台对室性心律失常的中药配伍规律,药物与证候之间的关系进行复杂网络分析。
2.3延胡索提取物治疗大鼠急性心肌梗死后室性心律失常的实验研究方法
建立大鼠急性心肌梗死模型,将wistar大鼠随机分为正常组、假手术组、模型组、美托洛尔组、参松养心胶囊组、延胡索提取物高、中、低剂量组。N-BT染色测量心肌梗死面积,ELASA法测定Na+-K+-ATPase和Ca2+-ATPase活性,免疫蛋白印迹法测定缝隙连接蛋白43(Connexin 43,CX43)及其磷酸化CX43 (Phospyo-CX43, P-CX43)的蛋白含量,及免疫组化法观察CX43及P-CX43的表达位置。从以上几个方面来探讨延胡索提取物对大鼠急性心肌梗死后室性心律失常的作用机制。
3.结果
3.1系统评价结果--中医药治疗冠心病室性早搏的Meta分析
与空白对照或西药对照相比,中医药可有效治疗冠心病室性早搏,减少冠心病室性早搏次数,差异有统计学意义(p<0.05)。Jadad评分表明研究质量大部分属于低质量。
3.2数据挖掘结果
入选了386例冠心病室性心律失常患者,男性201例,女性185例,平均年龄70.06±10.33岁。合并病及疾病亚型主要是高血压、心功能不全、心绞痛、陈旧心肌梗死、糖尿病。冠心病室性心律失常的主要证候为血瘀、气虚、痰浊。患者首次使用的中药主要是茯苓、丹参、当归、半夏、麦冬、甘草、红花、川芎、桃仁、陈皮,首次使用的中药主要为补气药、活血调经药、理气药。最常使用的抗心律失常药为美托洛尔、胺碘酮与慢心律。室性心律失常患者预后在冠心病心律失常患者中较差、无效与死亡率明显高于其他类型心律失常患者。冠心病室性心律失常药物-证候复杂网络挖掘分析显示,常见证候为气虚、血瘀、痰浊,与证候对应的药物主要是丹参、茯苓、当归、麦冬、赤芍、红花、川芎、甘草、半夏、桃仁、陈皮、五味子。
3.3延胡索提取物治疗大鼠急性心肌梗死后室性心律失常的实验研究结果
3.3.1心梗面积
在梗死区面积与梗死区面积／心室总面积上,延胡索提取物小、中剂量组及美托洛尔、参松养心胶囊治疗组均有缩小急性心肌梗死面积的作用(P<0.05)。
3.3.2 Na+-K+-ATPase与Ca2+-ATPase活性结果
与正常组比较,模型组的Na+-K+-ATPase与Ca2+-ATPase活性明显降低(P<0.01)。延胡索碱提取物组与其他药物治疗组均可以明显提高大鼠急性心肌梗死后降低的Na+-K+-ATPase与Ca2+-ATPase活性(P<0.01)。
3.3.3 CX43与P-CX43免疫蛋白印迹结果
与正常组比较,模型组的CX43及P-CX43蛋白含量明显减少(P<0.05)。延胡索提取物小、中剂量组及美托洛尔、参松养心胶囊组均能提高急性心肌梗死后降低的CX43与P-CX43的蛋白含量(P<0.05)。其中延胡索提取物中剂量组与美托洛尔组疗效相当。
3.3.4各组大鼠心脏大体病理形态学结果
HE染色结果显示,延胡索提取物治疗组及其他药物治疗组,肌纤维损伤程度减轻,大部分肌纤维完整,排列整齐,仅见局灶性纤维组织增生,淋巴细胞浸润,而模型组心肌纤维排列紊乱,部分胞浆溶解,纤维组织增生明显,伴玻璃样变,可见肉芽组织形成及坏死组织。
3.3.5 CX43与P-CX43免疫组化结果
正常组CX43与P-CX43主要分布在细胞端端连接处,即闰盘区域。而模型组,细胞结构被破坏,CX43与P-CX43表达明显降低,且出现侧边化现象明显。延胡索提取物治疗组与美托洛尔组、参松养心胶囊组,CX43与P-CX43表达较模型组明显增加,细胞结构损伤较模型组小,亦有侧边化现象。
4.结论
4.1系统评价提示中医药对冠心病室性早搏有一定的疗效及安全性,但因纳入研究质量较低,需更多高质量研究进一步验证。
4.2冠心病室性心律失常的主要证候为血瘀、气虚、痰浊,常用中药为丹参、茯苓、当归、麦冬、赤芍、红花、川芎、甘草、半夏、桃仁、陈皮、五味子,与证候相应的中药主要为补气药、活血调经药、理气药等。
4.3延胡索提取物能减少大鼠急性心肌梗死面积,改善心肌缺血损伤,提高梗死后心肌的Na+-K+-ATPase与Ca2+-ATPase活性和梗死后减少的CX43与P-CX43的蛋白含量,减少CX43与P-CX43侧边化现象,从而降低室性心律失常的发生。
1.1 To systematically review the effect and safety of Chinese medical treatment of coronary heart disease (CHD) patients with ventricular premature complexes (VPC), so as to provide evidence for Chinese medicine treating CHD patients with VPC.
1.2 Using the data mining technology to dig the data base "CHD platform of integrated clinical and scientific research", to investigate diagnose and treatment regularity of Chinese medicine treating CHD patients with VPC, and to explore the prescription and medication features.
1.3 From the aspects of proteomics, enzymology and immunohistochemical morphology, to explore the mechanism of Yanhusuo extract (YE) on rat model of ventricular arrhythmia (VA) after acute myocardial infarction (AMI), so as to provide experimental evidences for YE preventing ventricular arrhythmia from CHD, especially from AMI, and settle the foundation to explore the new medicine of YE.
2. Methods
2.1 Methods of systemic review
Databases of PubMed, CBM, CMCC, VIP, CNKI and WanFang were searched for all available data till February 2011. RevMan5.1.4 software was used to conduct meta-analysis. Jadad score was used to assess the quality of the included trials.
2.2 Methods of data mining
The data change-over and data loading for demography information general clinical characteristic、syndromes、therapeutic methods and Chinese medicine prescription were managed by SQL Server 2000 software. Multi-subject inquest and web analysis for the request of clinical need of VA in CHD were managed by Business Objects software. The syndromes distribution and TCM prescription of VA in CHD were dug and analyzed by Oracle 10g software. The Chinese medicine compatibility regularity and the relationship between Chinese medicine and syndromes were explored by complex networks analysis.
2.3 Methods of experimental research for YE treating VA after AMI in rats
To establish rat model of AMI, Wistar rats were randomly divided into normal group, sham group, model group, metoprolol group, Shensong Yangxin Capsule (SYC) group and low dosage、median dosagee and high dosage of YE groups. The infarction area was measured by N-BT staining. The Na+-K+-ATPase and Ca2+-ATPase activities were measured by ELASA method. Western Blot method was used to measure the protein levels of connexin43 (CX43) and phosphor-CX43 (P-CX43), and immnohistochemical method was used to observe the expression location of CX43 and P-CX43. From above all aspects to explore the mechanism of YE on rat VA model after AMI.
3. Results
3.1 Results of systematic review---the effect of Chinese medicine on CHD patients with VPC, a meta-analysis.
Compared with blank control group or western medicine group, Chinese medicine might treat CHD patients with VPC effectively, and also might reduce the VPC frequency (P<0.05). According to Jadad score, the quality of most of the trials was low.
3.2 Results of data mining analysis
386 CHD patients with VA aged 70.06±10.33 years in average were enrolled, including 201 males and 185 females. The subtypes and combined diseases were hypertension, heart failure, angina pectoris, old myocardial infarction,and diabetes mellitus. The main syndromes of CHD patients with VA were blood stasis, qi deficiency and phlegm-turbid. The first TCM prescription after admission mainly contained Fuling, Danshen, Danggui, Banxia, Maidong, Gancao, Honghua, Chuanxiong, Taoren, and Chenpi. The main functions of these Chinese medicines above were tonifying qi, activating blood and regulating qi. The main anti-arrhythmia medicines were metoprolol, amiodarone and mexiletine. The prognosis of CHD patients with VA was worse than the other types of CHD patients with arrhythmia, the ineffective ratio and mortality were much higher. The complex netmork analysis of medicine-syndrome showed that the main syndromes of CHD patients were qi deficiency, blood stasis and phlegm-turbid. The corresponded medicines for treating the main syndromes were Danshen, Fuling, Danggui, Maidong, Chishao, Honghua, Chuanxiong, Gancao, Banxia, Taoren, Chenpi and Wuweizi.
3.3 Results of experimental research into YE treating VA after AMI in rats
3.3.1 Result of myocardial infarction area
Compared with the model group, low dosage and median dosage group of Yanhusuo Extract, Metoprolol group and Shensong Yangxin Capsule group could reduce the myocardial infarction area and lower the ratio of myocardial infarction area/ventricle area (P<0.05).
3.3.2 Result of Na+-K+-ATPase and Ca2+-ATPase activities
Compared with the normal group, both the Na+-K+-ATPase and Ca2+-ATPase activities in model group were lowered obviously (P<0.01). The low、median、high dosage of YE and other medicine groups could improve the level of Na+-K+-ATPase and Ca2+-ATPase activities, compared with model group (P<0.01).
3.3.3 Result of protein level of CX43 and P-CX43 using Western Blot method.
Compared with normal group, the protein levels of CX43 and P-CX43 in model group were obviously lowered (P<0.05). Except the high dosage of YE group, the other medical groups could improve the reduced protein levels of CX43 and P-CX43 after AMI (P<0.05). In addition, the effect of median dosage of YE group was as good as Metoprolol group.
3.3.4 Result of pathomorphology in general of the rat hearts in all the groups
Hematoxylin and Eosin (HE) staining showed that the low、median、high dosage of YE and other medicine groups could relieve the muscle fiber injury. Most of muscle fibers in the rat hearts of these groups were intact and line up in order. Only local fibroplasias and lymphocytes infiltrating were seen. Nevertheless, in the model group, cardiac muscle fibers lined up disorderly. Plasmolysis, fibroplasias, glassy degeneration, granulation tissue and necrotic tissue were seen.
3.3.5 Result of immunohistochemical CX43 and P-CX43
In the normal group, CX43 and P-CX43 were mainly located at end-to-end apposition, also known as the myocardial cell intercalated disc region. In the model group, cellular structure was destroyed; CX43 and P-CX43 expression decreased obviously, and dislocated from end-to-end to side-to-side connections, also called lateralization. Compared with model group, the expression of CX43 and P-CX43 in YE groups, Metoprolol group and Shensong Yangxin Capsule group increased obviously, and just some of the cellular structures suffered from injury. However, some cardiocytes appeared lateralization.
4. Conclusion
4.1 The result of systematic review suggested that Chinese medicine could treat CHD patients with VPC effectively and safely. However, much more high quality researches are still needed to back up this result.
4.2 Blood stasis, qi deficiency and phlegm-turbid were the main syndrome elements of CHD patients with VA. The most of Chinese medicine used were Danshen, Fuling, Danggui, Chishao, Honghua, Chuanxiong, Gancao, Banxia, Taoren, Chenpi, and Wuweizi. Corresponded with the main syndrome, the functions of these Chinese medicines were tonifying qi, activating blood and regulating qi.
4.3 Yanhuosuo Extract could reduce the acute myocardial infarction area on rat AMI model, enhance the protective effect of ischemia injury, increase the activities of Na+-K+-ATPase and Ca2+-ATPase and the reduced protein level of CX43 and P-CX43 after AMI, and reduce the lateralization of CX43 and P-CX43, and accordingly reduce the genesis of ventricular arrhythmia. The mechanism of YE treating ventricular arrhythmia might be related to above all.
引文
[1]朱明军,王永霞.心律失常的中西医结合治疗.中国中西医结合杂志,2011,31(3)：428-432.
[2]戴梅,张大炜,旭升等.魏执真辨治快速性心律失常的临床经验.北京中医药,2011,30(5)：343-345.
[3]杨洁,张文高.张文高治疗心律失常三法.辽宁中医杂志,2011,38(9)：1887-1889.
[4]梁逸强,周端.周端教授辨治心律失常的经验撷萃.云南中医学院学报,2011,34(6)：38-40.
[5]祁慧霞,牛天福,李娟.中医治疗室性期前收缩的研究进展.中西医结合心脑血管病杂志,2011,9(12)：1501-1502.
[6]尹克春,林敏婷,刘淑娟等.冠心病室性心律失常的中医证候分布规律临床观察.辽宁中医杂志,2008,35(4)：536-538.
[7]杨涛.裴正学教授治疗心律失常的经验.中国社区医师·医学专业,2011,13(25)：150-151.
[8]周仲瑛.中医内科学.中国中医药出版社,北京：2003年.
[9]徐贵成.心律失常治疗的中医优势.中国医院用药评价与分析,2011,11(9)：770
[10]丁碧云.徐经世治疗心律失常证治规律探讨.中西医结合心脑血管病杂志,2011,9(1)：112-114
[11]袁灿宇,袁智宇,袁晓宇.袁海波教授治疗冠心病心律失常经验探讨.中医学报,2010,25(5)：874-875.
[12]李庆海,李庆玉,史海霞.心悸宁丸治疗快速型心律失常的临床观察.中医学报,2009,24(6)：44-45.
[13]张洁,刘建东,张雅玲等.悸安冲剂治疗冠心病心律失常疗效观察.上海中医药杂志,2005,39(8)：13-14.
[14]杨淑媛,黄永生.温阳止悸饮治疗冠心病劳累性稳定型心绞痛室性期前收缩阳(气)虚气滞候的临床观察.吉林中医药,2007,27(9)：13-14.
[15]李芳,李霞,丁瑜.炙甘草汤和桃红四物汤加味治疗冠心病室性早搏疗效观察.辽宁中医药大学学报,2010,12(8)：146-147.
[16]陈国通,邹襄谷,陈永忠.炙甘草汤联合心律平治疗气阴两虚型冠心病并发室性心律失常50例临床观察.福建中医药,2010,41(3)：11-12.
[17]王东琦,苏显明,崔长琮.J波和J波综合征.中国心脏起搏与心电生理杂志,2008,22(1)：4
[18]郭继鸿.猝死高危预警的新指标：缺血性J波.中国心脏起搏与心电生理杂志,2008,22(1)：6
[19]郭继鸿.抗心律失常中药的应用优势.中国循证心血管医学杂志,2010,2(4)：198-201.
[20]刘元伟,郭继鸿,张萍等.稳心颗粒甘松提取物对大鼠心室肌细胞钠电流和
瞬时外向钾电流激活动力学的影响.中国心脏起搏与心电生理杂志,2009,23(6)：533-535.
[21]卢志红,吴旭斌,刘伶等.稳心颗粒对急性冠脉综合征合并心律失常影响的多中心临床研究.实用临床医药杂志,2010,14(1)：59-62.
[22]任乃照,张建中.稳心颗粒治疗冠心病期前收缩116例.中西医结合心脑血管病杂志,2009,7(5)：603-604.
[23]刘建和,莫观海,唐路等.稳心颗粒治疗冠心病室性期前收缩的临床研究.中西医结合心脑血管病杂志,2007,5(10)：922-924.
[24]王万华,徐显华,钟景页等.稳心颗粒治疗老年人冠心病室性期前收缩的临床疗效.中西医结合心脑血管病杂志,2006,4(10)：847-848.
[25]徐涛,张煜,王昊等.参松养心胶囊对兔跨室壁复极离散度的影响.疑难病杂志,2011,10(12)：916-918.
[26]孙莉萍,李宁,张树林等.参松养心胶囊对Hhcn4起搏电流通道的影响.中西医结合心脑血管病杂志,2010,8(5)：530-531
[27]吴以岭,谷春华,高学东等.参松养心胶囊治疗冠心病室性早搏的随机双盲多中心临床研究.疑难病杂志,2007,6(8)：449-452.
[28]杨天伦,吴声滨,谢启应等.参松养心胶囊治疗冠心病室性早搏疗效及对生活质量影响的对比研究.中国中医基础医学杂志,2009,15(12)：932-935.
[29]胡有志,石杰,向楠等.参松养心胶囊治疗冠心病室性早搏的临床研究(附气阴两虚、心络瘀阻型心悸病例20例).中西医结合心脑血管病杂志,2005,3(9)：760-762.
[30]陈金国,王东平,陶春明等.参松养心胶囊联合通心络胶囊治疗冠心病心力衰竭伴室性早搏的临床研究.疑难病杂志,2008,7(4)：195-197.
[31]刘玉梅,周宇宏,单宏丽等.延胡索乙素对豚鼠单个心室肌细胞钾离子通道的影响[J].中国药理学通报,2005,21(5)：599-601.
[32]唐其柱,黄峥嵘,史锡腾等.甘松提取物对家兔心室肌细胞钠、钙通道的影响.中华心血管病杂志,2004,32(增刊)：267.
[33]张婉,潘振伟,冯铁明等.苦参碱对缺血性心室肌细胞快速延迟整流钾电流的作用.中国药理学通报,2008,24(3)：322-326.
[34]SHAN Hong-li,YANG Bao-feng,ZHOU Yu-hong,et al.Effects of matrine on acontine-induced electrophysiological changes in rat ventricular myocytes. Journal of Chinese Pharmaceutical Science,2004,13(3):193-198
[35]郭治彬,付金国,赵勇等.氧化苦参碱对冠心病患者心律失常及心率变异性的影响.中国中西医结合杂志,2006,26(4)：311-315.
[1]Uemura K, Ueyama T, Shintani-Ishida K, et al. An autopsy report on four sudden cardiac death cases by immobilization.Int Med J,2008,15:301-305.
[2]Tsuchida M, Kawashiri MA, Teramoto R, et al. Impact of severe earthquake on the occurrence of acute coronary syndrome and stroke in a rural area of Japan. Circ J,2009,73:1243-1247.
[3]Kana Unuma, Kaori Shintani-Ishida, Kensuke Tsushima, et al. Connexin-43 redistribution and gap junction activation during forced restraint protects against sudden arrhythmic death in rats. Circ J,2010,74:1087-1095.
[4]De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res,2004,61:208-217.
[5]Giilistan Mese, Gabriele Richard, Thomas W. White. Gap Junctions:basic structure and function.Journal of Investigative Dermatology,2007,127:2516-2524.
[6]Laird DW.Life cycle of connexins in health and disease. Biochem J,2006,394: 527-543
[7]Gaietta G, Deerinck TJ, Adams SR, et al. Multicolor and electron microscopic imaging of connexin trafficking. Science,2002,296:503-507
[8]Evans WH, De VE, Leybaert L. The gap junction cellular internet:connexin hemichannels enter the signalling limelight. Bio chem J,2006,397:1-14
[9]Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res,2004,62:228-232.
[10]Van Veen TAB, Van Rijen HVM, Opthof T. Cardiac gap junction channels: modulation of expression and channel properties.Cardio Vasc Res,2001,51:217-229.
[11]Boengler K, Dodoni G, Rodriguez-Sinovas A, et al. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardio Vase Res,2005,67:234-244.
[12]Goldberg GS, Valiunas V, Brink PR. Selective permeability of gap junction channels. Biochim Biophys Acta,2004,1662:96-101
[13]Severs NJ, Coppen SR, Dupont E, et al. Gap junction alterations in human cardiac disease. Cardiovasc Res,2004,62:368-377.
[14]Severs NJ, Dupont E, Thomas N, et al. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol,2006,42:228-242.
[15]Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardio vase Res,2004,62:228-232.
[16]Saez JC, Berthoud VM, Branes MC, et al. Plasma membrane channels formed by connexins:their regulation and functions. Physiol. Rev,2003,83:1359-1400.
[17]Joell L. Solan, Paul D. Lampc. Key connexin 43 phosphorylation events regulate the gap junction life cycle. J Membrane Biol,2007,217:35-41
[18]Delmar M, Coombs W, Sorgen P, et al. Structural bases for the chemical regulation of connexin43 channels. Cardiovasc Res,2004,62:268-275.
[19]Joell L.SOLAN, Paul D.LAMPE.Connexin43 phosphorylation:structural changes and biological effects.Biochem. J,2009,419:261-272.
[20]TenBroek EM, Lampe PD, Solan JL, et al. Ser364 of connexin43 and the upregulation of gap junction assembly by cAMP.J Cell Biol,2001,155:1307-1318.
[21]Thomas M. Bodenstine, Kedar S. Vaidya, Aimen Ismail, et al. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.Cancer Res,2010,70:10002-10011.
[22]Keiichiro YOGO, Takuya OGAWA, Motofusa AKIYAMA, et al. PKA implicated in the phosphorylation of CX43 induced by stimulation with FSH in rat granulosa cells. J. Reprod.Dev,2006,52(3):321-328.
[23]Xiaoyong Bao, Luis Reuss, Guillermo A. Altenberg. Regulation of purified and reconstituted connexin 43 hemichannels by protein kinase C-mediated phosphorylation of serine 368.Journal of Biological Chemistry,2004,279 (19): 20058-20066.
[24]Jose F. Ek-Vitorin, Timothy J. King, Nathanael S. Heyman, et al. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circulation Research,2006,98:1498-1505
[25]Paul D. Lampe, Erica M. TenBroek, Janis M. Burt, et al. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. The Journal of Cell Biology,2000,19(7):1503-1512.
[26]Bradley W. Doble, Peipei Ping, Elissavet Kardami. The ε subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation.Circulation Research,2000,86:293-301.
[27]Edgar Rivedal, Hanne Opsahl. Role of PKC and MAP kinase in EGF-and TPA-induced connexin43 phosphorylation and inhibition of gap junction intercellular communication in rat liver epithelial cells.Carcinogenesis,2001,22 (9):1543-1550.
[28]Cottrell GT, Lin R, Warn-Cramer BJ, et al. Mechanism of v-Src and mitogen activated protein kinase-induced reduction of gap junction communication.American Journal of Physiology,2003,284:C511-C520.
[29]G. Trevor Cottrell, Rui Lin, Bonnie J. et al. Mechanism of v-Src and mitogen-activated protein kinase-induced reduction of gap junction communication. Am J Physiol Cell Physiol,2003,284:511-520.
[30]Solveig Sirnes, Ane Kjenseth, Edward Leithe, Edgar Rivedal. Interplay between PKC and the MAP kinase pathway in connexin43 phosphorylation and inhibition of gap junction intercellular communication.Biochemical and Biophysical Research Communications,2009,382(1):41-45.
[31]Stefan D. Gross, Calvin Simerly, Gerald Schatten, Richard A. Anderson. A casein kinase Ⅰ isoform is required for proper cell cycle progression in the fertilized mouse oocyte. J. Cell Sci,1997,110:3083-3090
[32]Jiangyu Zhu, Futoshi Shibasaki, Roydon Price, et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase Ⅰ and MEKK1. Cell Press, 1998,95(5):851-861.
[33]Jochen Walter, Regina Fluhrer, Bianka Hartung, et al. Phosphorylation regulates intracellular trafficking of β-Secretase. J. Biol. Chem,2001,276 (18):14634-14641.
[34]Renee M. McKay, John M. Peters, Jonathan M. Graff. The casein kinase Ⅰ family in wnt signaling.Developmental Biology,2001,235(2):388-396.
[35]Cynthia D. Cooper, Paul D. Lampe. Casein kinase 1 regulates connexin-43 gap junction assembly, J.Biol.Chem,2002,277(47):44962-44968.
[36]Madhuri Pahujaa, Michael Anikin, Gary S. Goldberg. Phosphorylation of connexin43 induced by Src:regulation of gap junctional communication between transformed cells. Experimental cell research,2007,313(20):4083-4090.
[37]Rui Lin, Bonnie J. Warn-Cramer, Wendy E. Kurata, Alan F. Lau.v-Src phosphorylation of connexin 43 on Tyr247 and Tyr265 disrupts gap junctional communication. J.CELL.Biol,2001,154(4):815-827.
[38]Ben N. G. Giepmans, Trudi Hengeveld, Friso R. Postma, Wouter H. Moolenaar.Interaction of c-Src with gap junction protein connexin-43.J.Biol. Chemi,2001,276 (11):8544-8549.
[39]Teunissen BE, Bierhuizen MF. Transcriptional control of myocardial connexins.Cardiovasc Res,2004,62:246-255.
[40]Saffitz JE, Kleber AG. Effects of mechanical forces and mediators of hypertrophy on remodeling of gap junctions in the heart.Circ Res,2004,94:585-591.
[41]Oxford EM, Musa H, Maass K, et al. Connexin43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells.Circ Res,2007,101:703-711.
[42]Bruce AF, Rothery S, Dupont E, et al. Gap junction remodeling in human heart failure is associated with increased interaction of connexin43 with ZO-1. Cardiovasc Res,2008,77:757-765.
[43]Li J, Patel VV, Radice GL. Dysregulation of cell adhesion proteins and cardiac arrhythmogenesis. Clin Med Res,2006,4:42-52.
[44]Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res,2002,54:361-79.
[45]Ai Z, Fischer A, Spray DC, Brown AM, Fishman GI.Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Invest,2000,105:161-171
[46]Chen XY, Bonne S, Hatzfeld M, van Roy F, Green KJ.Protein binding and functional characterization of plakophilin evidence for its diverse roles in desmosomes and β-catenin signaling. J Biol Chem,2002,277:10512-10522.
[47]Nicholas J. Severs, Alexandra F. Bruce, Emmanuel Dupont, Stephen Rothery.Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovascular Research,2008,80:9-19.
[48]Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov,2006,5:1034-1049
[49]YU zhibin, SHENG Juanjuan.Remodeling of cardic gap junctions and arrhythmias.Acta Physiologica Sinica,2011,63(6):586-592.
[50]N.RIBULOVA, V. KNEZL, E.OKRUHLICOVA, J.SLEZAK. Myocardial gap junctions:targets for novel approaches in the prevention of life-threating cardiac arrhythmias. Physiol. Res,2008,57(Suppl.2):1-13.
[51]Gutstein DE, Morley GE, Vaidya D, et al. Heterogeneous expression of gap junction channels in the heart leads to conduction defects and ventricular dysfunction.Circulation,2001,104:1194-1199.
[52]Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in CX43-deficient mice.Circulation,2000,101:547-52.
[53]Danik SB, Liu F, Zhang J, et al. Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res,2004,95:1035-1041.
[54]Poelzing S, Rosenbaum DS. Altered connexin43 expression produces arrhythmia substrate in heart failure.Am J Physiol Heart Circ Physiol,2004, 287:H1762-H1770.
[55]Severs NJ, Bruce AF, Dupont E, Rothery S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res,2008,80:9-19.
[56]Matsushita T, Oyamada M, Fujimoto K, et al. Remodeling of cell-cell and cell-extracellular matrix interactions at the border zone of rat myocardial infarction.Circ Res,1999,85:1046-1055.
[57]Lampe PD, Cooper CD, King TJ, Burt JM. Analysis of connexin43 phos-phorylated at S325, S328 and S330 in normoxic and ischemic heart.J Cell Sci, 2006,119:3435-3442.
[58]Gutstein DE, Morley GE, Tamaddon H, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43.Circ Res,2001,88:333-39.
[59]Danik SB, Rosner G, Lader J, et al. Electrical remodeling contributes to complex tachyarrhythmias in connexin43-deficient mouse hearts. FASEB J,2008, 22:1204-1212.
[60]Kaprielian RR, Gunning M, Dupont E, et al, Underwood R, et al. Down-regulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation,1998,97:651-660.
[61]Yao JA, Hussain W, Patel P, et al. Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts.Circ Res,2003, 92:437-443.
[62]Akar FG, Nass RD, Hahn S, et al. Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure.Am J Physiol Heart Circ Physiol,2007,293:H1223-H1230.
[63]Uzzaman M, Honjo H, Takagishi Y, et al.Remodeling of gap-junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension.Circ Res,2000,86:871-878.
[64]Peters NS, Severs NJ, Coromilas J, Wit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation,1997,95:988-996.
[65]Sepp R, Severs NJ, Gourdie RG.Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart,1996,76:412-17.
[66]Papp R, G onczi M, Kovacs M, et al. Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischemic preconditioning. Cardiovasc Res,2007,74(3):396-405
[67]Axelsen LN, Stahlhut M, Mohammed S, et al. Identification of ischemia-regulated phosphorylation sites in connexin43:A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Mol Cell Cardiol,2006,40 (6):790-798.
[68]Michael P. O'Quinn, Joseph A. Palatinus, Brett S. Harris, et al. A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circulation Research,2011, 108:704-715.
[69]Tetsuji Miura, Yoshito Ohnuma, Atsushi Kuno, et al. Protective role of gap junctions in preconditioning against myocardial infarction. Am J Physiol Heart Circ Physiol,2004,286:H214-H221.
[70]Shahriar Iravanian, Ali A.Sovari, Harvey A.Lardin, et al. Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43. J Mol Med (Berl),2011,89(7):677-687.
[71]Benjamin F. Remo, Jiaxiang Qu, Frank M. Volpicelli, et al. Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent arrhythmias. Circulation Research,2011,108:1459-1466
[72]Miura T, Ohnuma Y, Kuno A, et al. Protective role of gap junctions in preconditioning against myocardial infarction. Am. J. Physiol Heart Circ Physiol, 2004,55(1):214-2211
[73]Wattamon Srisakuldee, Maya M. Jeyaraman, Barbara E. Nickel, et al. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovascular Research,2009,83:672-681.
[1]马胜兴,陈可冀,王荣金.延胡索碱治疗过早搏动的临床研究[J].中华心血管病杂志,1983,11(1)：6-9.
[2]马胜兴,陈可冀,马玉玲,等.延胡索抗心律失常作用的初步实验[J].中药通报,1985,10(11)：41-42.
[3]汪大金,毛焕元,黄从新.植物性钙拮抗剂颅痛定的抗心律失常临床疗效及其电生理作用[J].同济医科大学学报,1993,22(5)：322-324.
[4]汪大金,毛焕元,黄从新,等.罗通定在预激综合征病人中的临床电生理作用[J].中华心血管病杂志,1993,21(5)：286.
[5]唐召力.颅痛定治疗预激综合征所合并的快速室上性心律失常[J].急诊医学,1999,8(6)：399-400.
[6]韩凤波.硫酸罗通定注射液治疗快速室上性心律失常[J].天津药学,2002,14(1)：44-45.
[7]姚伟星,夏国瑾,曾维忠,等.7-氯苄基四氢巴马汀的抗心律失常作用[J].中国药理学与毒理学杂志,1995,9(3)：220-223.
[8]闵清,吴基良,罗德生,等.7-氯苄基四氢巴马汀对L2甲状腺素诱发大鼠心肌肥厚及左心室肌原纤维Na+-K+-ATPase活力的影响[J].咸宁学院学报(医学版),2004,18(6)：385-387.
[9]闵清,白育庭,吴基良,等.7-氯苄基四氢巴马汀对豚鼠离体心房的作用[J].咸宁学院学报,2000,14(2)：97-99.
[10]张桂清,曾秋棠,曹林生,等.四氢巴马汀对氯化铯诱发家兔在体心脏早后除极和触发性室性心律失常作用的研究[J].中华心律失常学杂志,2000,4(3)：208.
[11]曾秋棠,张桂清,曹林生,等.四氢巴马汀抗触发性室性心律失常作用机制的研究[J].中华内科杂志,2000,39(10)：667-669.
[12]杨宝峰,姚伟星,夏国瑾,等.7-溴化乙氧苯四氢巴马汀的抗心律失常作用[J].中国药理学与毒理学杂志,1990,4(2)：95-98.
[13]杨宝峰,陈庆文,张永春,等.7-溴化乙氧苯四氢巴马汀抑制外向钾电流和尾电流[J].中国药理学通报,1994,10(5)：352-354.
[14]杨宝峰,宗贤刚,王刚,等.7-溴化乙氧苯四氢巴马汀抗心律失常作用的机理[J].药学学报,1990,25(7)：481-484.
[15]曾维忠,夏国瑾,姚伟星,等.苄基四氢巴马汀对心肌动作电位及浦氏纤维跨膜钾、钙离子流的影响[J].中国药理学报,1990,11(4)：314-317.
[16]刘玉梅,周宇宏,单宏丽,等.延胡索乙素对豚鼠单个心室肌细胞钾离子通道 的影响[J].中国药理学通报,2005,21(5)：599-601.
[17]Miake J, Marban E, Nuss HB. Functional role of inward rectifier current in heart probed by Kir2.1 over-expression and dominant-negative suppression.J Clin Invest,2003,111(10):1529-1536.
[18]程龙献,毛焕元,戴水平,等.颅痛定对单个豚鼠心室肌细胞膜钙通道电流的影响[J].临床心血管病杂志,1995,11(3)：170-172.
[19]赵听,汤浩,王亚杰,等.脱氢紫堇碱对正常和低氧豚鼠心肌细胞内钙的影响[J].中国应用生理学杂志,2003,19(3)：222-225.
[20]黄亚莉,陆彤,蒋文平.内皮素对豚鼠心室肌细胞触发电活动的影响[J].中华心血管病杂志,1995,23(5)：381-383.
[21]马建群,毛焕元,曹林生,等.颅痛定对心肌缺血-再灌注性室性心律失常及血浆内皮素-1浓度的影响[J].中国危重病急救医学,1993,10(1)：7-9.
[22]马建群,毛焕元,曹林生,等.颅痛定对心肌缺血再灌注性室性心律失常及血浆去甲肾上腺素浓度的影响[J].中国实用内科杂志,2002,22(8)：485-486.
[23]汪永孝,郑云敏,谭月华.四氢巴马汀抗缺血再灌注心律失常的作用及其机理[J].中国药理学通报,1993,9(5)：358-361.
[24]闵清,白育庭,吴基良,等.罗通定对大鼠心肌缺血的保护作用[J].医药导报,2001,20(9)：554-555.
[25]闵清,白育庭,舒思洁.四氢巴马汀对大鼠心肌缺血再灌注损伤的保护作用[J].中国误诊学杂志,2007,7(23)：5462-5464.
[1]国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组报告缺血性心脏病的命名及诊断标准.中华心备管病杂志,1981,9(1)：75-76.
[2]陈灏珠.实用内科学[M].第13版.人民卫生出版社,北京：2009：397-1400.
[3]郑筱萸.中药新药临床研究指导原则.北京：中国医药科技出社,2002：69-73.
[4]邓可刚,何庆.循证医学证据的检索与利用(第2版)[M].北京：人民卫生出版社,2008,186.
[5]李博,循证检索实例(见聂绍平主编《医学信息搜集的途径和方法》第25章循证医学专业数据库)[M],人民卫生出版社,北京：2008,558.
[6]Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized clinical trials:is blinding necessary? Control Clin rials,1996,17:1-12.
[7]胡有志,石杰,向楠等.参松养心胶囊治疗冠心病室性早搏的临床研究：附气阴两虚、心络瘀阻型心悸病例20例.中西医结合心脑血管病杂志,2005,3(9)：760-762.
[8]吴以岭,谷春华,高学东等.参松养心胶囊治疗冠心病室性早搏的随机双盲多中心临床研究.疑难病杂志,2007,6(8)：449-452
[9]徐贵成,霍保民,吴以岭等.参松养心胶囊治疗冠心病室性早搏随机双盲、阳性药对照、多中心临床研究.中国中医基础医学杂,2003,9(3)：37-40
[10]刘建和,易刚强,程丑夫.柴胡三参汤治疗冠心病室性期前收缩临床研究.中国中医药信息杂志,2005,12(11)：13-15
[11]罗庆华.定悸稳心汤治疗冠心病室性期前收缩的临床研究.中国医药导报,2007,4(32)：77-78
[12]张琼,周明学,黄永生等.复律保心平口服液治疗冠心病室性早搏的初步临床观察.中国中西医结合杂志,2008,28(6)：509-512
[13]沈安明,谢轶群,吕军.健心胶囊治疗冠心病室性早搏临床观察.实用中西医结合临床,2008,8(6)：11-12
[14]李珂,孙兰军,高克俭等.通脉养心丸治疗冠心病室性早搏(气阴两虚证)多中心临床研究.中西医结合心脑血管病杂志,2010,8(4)：401-403
[15]杨靖,何劲松,杨小英.稳心颗粒合用胺碘酮治疗冠心病室性早搏临床观察.广西中医学院学报,2005,8(3)：18-20
[16]刘建和,莫观海,唐路等.稳心颗粒治疗冠心病室性期前收缩的临床研究.中西医结合心脑血管病杂志,2007,5(10)：922-924
[17]沈红权,黄秀英,曾帼英等.心复平治疗冠心病合并频繁室性早搏的临床研 究.中华临床杂志,2005,1(1)：13-14
[18]李玉峰,鲁卫星.心脉安片治疗冠心病室性早搏40例临床观察.北京中医药大学学报,2003,26(3)：67-69.
[19]李佳,刘淑荣.炙甘草汤加味治疗冠心病室性早搏的临床研究.2009年会议集：仲景医学求真(续三)：434-442.
[20]凌静.中西医结合治疗冠心病室性早搏45例临床观察.中医药导,.2007,13(2)：28-29.
[1]中华医学会心血管病学分会.急性心肌梗死诊断和治疗指南.中华心血管病杂志,2001,29(12)：710-725.
[2]中华医学会心血管病学分会,中国生物医学工程学会心脏起搏与心电生理分会,中华心血管病杂志编辑委员会,中国心脏起搏与心电生理杂志编辑委员会.室上性快速心律失常治疗指南.中华心血管病杂志,2005,33(1)：2-15
[3]陈新.黄宛临床心电图学(第六版)[M].北京：人民卫生出版社.2009,235-358.
[4]中国中西医结合学会心血管病专业委员会.冠心病中医辨证标准.中国中西医结合杂志,1991,11(5)：257.
[5]Douglas P. Zipes, A. John Camm, Martin Borggrefe, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary:A report of the American College of Cardiology/AmeriCan Heart Association task force and the European Society of Cardiology Committee for practice guidelines (Writing Committee to
develop guidelines for management o f patients with ventricular arrhythmias and the prevention of sudden cardiac death) Developed in collaboration with the
European Heart Rhythm Association and the Heart Rhythm Society. European Heart Journal,2006,27:2099-2140.
[6]吴立群,戚文航.心力衰竭时的心律失常与猝死.内科急危重症杂志,2005,11(6)：249-252
[7]马胜兴,陈可冀,王荣金.延胡索碱治疗过早搏动的临床研究.中华心血管病杂志,1983,11：6-10.
[8]马胜兴,陈可冀,马玉玲,包晓峰.延胡索抗心律失常作用的初步实验.中药通报,1985,11：41-42.
[9]刘剑刚,刘立新,马晓斌,等.延胡索碱注射液对大鼠实验性急性心肌梗塞和红细胞流变性的作用.中药新药与临床药理,2000,2：76-79.
[10]Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing:summary article:a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to update the 1997 exercise testing guidelines). J Am Coll Cardiol, 2002,40:1531-1540.
[11]Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations.N Engl J Med, 2000,343:826-833.
[12]杨洁,张文高.张文高治疗心律失常三法.辽宁中医杂志,2011,38(9)：1887-1889.
[13]周仲瑛.中医内科学.中国中医药出版社,北京：2003.
[14]徐贵成.心律失常治疗的中医优势.中国医院用药评价与分析,2011,11(9)：770
[15]张京春,谢元华.陈可冀院士辨治冠心病医案的数据挖掘.世界中西医结合杂志,2008,3(1)：4-5,7.
[16]Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, et al.2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/Non ST-elevation myocardial infarction:A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation,2011,123:1-154.
[17]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南.中华心血管病杂志,2007,35(4)：295-304.
[18]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志,2010,38(8)：675-690.
[19]Poole JE, Bardy GH, Sudden Cardiac Death. In:Zipes DP, Jalife J, eds. Cardiac Electrophysiology:From cell to bedside.3rd edn. Philadelphia, PA:W.B. Saunders Company,2000,615-640.
[20]Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation,2000,102:724-747.
[21]ECC Committee, Subcommittee and task forces of the American Heart Association.2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care.Circulation,2005,112:Ⅳ1-Ⅳ203.
[1]邵博一.稳心颗粒联合阿托伐他汀治疗缺血性心律失常的临床研究.中国实用医药.2007,2(4)：69-70.
[2]苏显明,王东琦,于忠祥等.急性心肌缺血犬心肌细胞瞬时外向钾电流和跨壁复极离散度变化致心律失常机制研究.临床心血管病杂志,2006,22(3)：140-144.
[3]施慧,龙子江,王靓等.宁心律康颗粒抗急性心肌缺血诱发心律失常的实验研究.中成药.2011,33(6)：1044-1046.
[4]陈修,陈维州,曾贵云.心血管药理[M].3版,北京：人民卫生出版社.2002：425-431.
[5]De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res.2004,61:208-217.
[6]李荣,吴伟,李文等.延胡索碱预处理对大鼠心肌缺血再灌注心律失常的干预作用.中药新药与临床药理.2010,21(3)：237-240.
[7]刘剑刚,刘立新,马晓斌等.延胡索碱注射液对大鼠实验性急性心肌梗死和红细胞流变性的作用.中药新药与临床药理.2000,11(2)：76-79.
[1]姚泰.生理学.人民卫生出版社,北京,2006：28-29.
[2]杨孝芳,刘小雨,习君萍.心肌缺血再灌注损伤的钙信号调节.中国临床康复,2006,10(44)：93-95.
[3]Zhao SX, Lee LM, Nearing BD, et al.Suppression of Calcium-induced repolarization heterogeneity as a mechanism of nitroglycerin's antiarrhythmic action.J Cardiovasc Pharmacol,2006,48:22-29.
[4]Liu J, Tian J, Haas M, et al. Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na+and Ca2+ concentrations.J Biol Chem,2000,275:27838-27844.
[5]Xie Z, Cai T. Na+-K+-ATPase-mediated signal transduction:from protein interaction to cellular function.Mol Interv,2003,3:157-168.
[6]Xu K.Y. Activation of Na+-K+-ATPase. Biochem Biophys Res Commun,2005, 338:1669-1677.
[7]Lee DI, Klein MG, Zhu W, et al. Activation of Na+-K+-ATPase modulates cardiac L-type Ca2+channel function. Mol Pharmacol,2009,75:774-81.
[8]Jin Zheng, Xiuxian Koh, Fei Hua, et al. Cardioprotection induced by Na+/K+-ATPase activation involves extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/Akt pathway. Cardiovascular Research,2011,89:51-59.
[9]P. KAPLAN, M. MATEJOVI COVA, P. HERIJGERS, et al. Lack of the effect of superoxide dismutase and catalase on Na+-K+-ATPase activity in stunned rabbit hearts.Physiol.Res(Suppl.2),2008,57:S61-S66.
[10]Stefanon, J.R. Cade, A.A. Fernandes, et al. Ventricular performance and Na+-K+-ATPase activity are reduced early and late after myocardial infarction in rats.Brazlilian Journal of MediCal and BiologiCal Research,2009,42:902-911.
[11]Javier Inserte, David Garcia-Dorado, Victor Hernando, et al. Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circulation Research,2005, 97:465-473.
[12]Singh RB, Dhalla NS.Ischemia-reperfusion-induced changes in sarcolemmal Na+/K+-ATPase are due to the activation of calpain in the heart. Can J Physiol Pharmacol,2010,88(3):388-397.
[13]Javier Inserte, David Garcia-Dorado, Victor Hernando, et al. Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion. Cardiovascular Research,2006,70:364-373.
[14]Larissa Lipskaia, Elie R Chemaly, Lahouaria Hadri, et al. Sarcoplasmic reticulum Ca2+ATPase as a therapeutic target for heart failure. Expert Opinion on BiologiCal Therapy Journal,2010,10(1):29-41.
[15]王永亮,范晓燕,刘关省等.心衰心肌细胞肌浆网钙泵对兴奋收缩偶联功能的影响.电子显微学报,2010,29(5)：486-490.
[16]Cho-Kai Wu, Chuen-Den Tseng, Yin-Tsen Huang, et al. Angiotensin II does not influence expression of sarcoplasmic reticulum Ca2+-ATPase in atrial myocytes. Journal of Renin-Angiotensin-Aldosterone System.2009,10(3):121-126.
[17]Hui Sun, Denis Chartier, Normand Leblanc, et al.Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res,2001,49:751-761.
[18]Christian E. Zaugg, Peter T. Buser. When calcium turns arrhythmogenic: intracellular calcium handling during the development of hypertrophy and heart failure. Croatian MediCal Journal,2001,42(1):24-32.
[19]Simon Sedej, Frank R. Heinzel, Stefanie Walther, et al. Na+-dependent SR Ca2+overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovascular Research,2010,87:50-59.
[20]U. Ravens, D. Dobrev.Regulation of sarcoplasmic reticulum Ca2+-ATPase and phospholamban in the failing and nonfailing heart.Cardiovascular Research,2000, 45:245-252.
[21]Przemyslaw Leszek, Malgorzata Szperl, Anna Klisiewicz, et al. Alteration of myocardial sarcoplasmic reticulum Ca2+-ATPase and Na+-Ca2+exchanger expression in human left ventricular volume overload. European Journal of Heart Failure,2007,9:579-586.
[22]Sufen Wang, Jeejabai Radhakrishnan, Iyad M. Ayoub, et al. Limiting sarcolemmal Na+entry during resuscitation from ventricular fibrillation prevents excess mitochondrial Ca2+accumulation and attenuates myocardial injury. J Appl Physiol,2007,103:55-65.
[23]Waldenstrom A, Ronquist G, Aberg AM, et al. Ischaemic preconditioning reduces myocardial calcium overload in coronary-occluded pig hearts shown by continuous in vivo assessment using microdialysis. Clin Physiol Funct Imaging, 2012,32(2):133-138.
[24]O.D. Pedersen, H. Bagger, L. Kober, C. Torp-Pedersen. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction.TRACE study group. Eur Heart J,1999,20:748-754.
[25]W. Haverkamp, H. Gulker, G. Hindricks, et al. Effects of beta-blockade on the incidence of ventricular tachyarrhythmias during acute myocardial ischemia: experimental findings and clinical implications. Basic Res Cardiol,1990,95: 293-303.
[26]G.Olsson, J.Wikstrand, I.Warnold, et al. Metoprolol-induced reduction in postinfarction mortality:pooled results from five double-blind randomized trials. Eur Heart J,1992,13(1):28-32.
[27]John McMurray, Lars Kober, Michele Robertson, et al. Antiarrhythmic effect of Carvedilol after acute myocardial infarction:results of the Carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology,2005,45(4):525-530.
[28]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.p肾上腺素能受体阻滞剂在心血管疾病应用专家共识.中华心血管病杂志,2009,37(3)：195-209.
[29]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志,2010,38(8)：675-690.
[30]李荣,吴伟,李文晞等.延胡索碱预处理对缺血再灌注心肌钙泵及钠钾泵活性的影响.辽宁中医杂志,2010,37(8)：1613-1615.
[1]Severs NJ, Coppen SR, Dupont E, et al. Gap junction alterations in human cardiac disease. Cardiovasc Res,2004,62:368-377.
[2]Severs NJ, Dupont E, Thomas N, et al. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol,2006,42:228-242.
[3]Sawa Kostin, Markus Rieger, Sebastian Dammer, et al. Gap junction remodeling and altered connexin43 expression in the failing human heart. Molecular and Cellular Biochemistry,2003,242:135-144.
[4]David E.Gutstein, Gregory E.Morley, Houman Tamaddon, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circulation Research,2001,83:333-339.
[5]Uemura K, Ueyama T, Shintani-Ishida K, et al.An autopsy report on four sudden cardiac death cases by immobilization.Int Med J,2008,15:301-305.
[6]Tsuchida M, Kawashiri MA, Teramoto R, et al.Impact of severe earthquake on the occurrence of acute coronary syndrome and stroke in a rural area of Japan. Circ J,2009,73:1243-1247.
[7]Kana Unuma, Kaori Shintani-Ishida, Kensuke Tsushima, et al. Connexin-43 redistribution and gap junction activation during forced restraint protects against sudden arrhythmic death in rats. Circ J,2010,74:1087-1095.
[8]Marisol Ruiz-Meana, Antonio Rodri'guez-Sinovas, Alberto Cabestrero, et al. Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischemia-reperfusion injury. Cardiovascular Research,2008,77:325-333.
[9]Nicholas J.Severs, Alexandra F.Bruce, Emmanuel Dupont, Stephen Rothery. Remodeling of gap junctions and connexin expression in diseased myocardium. Cardiovascular Research,2008,80:9-19.
[10]De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res,2004,61:208-217.
[111]Zeevi-Levin N, Barac YD, Reisner Y, et al. Gap junctional remodeling by hypoxia in cultured neonata 1 rat ventricular myocytes.Cardiovasc Res,2005, 66:64-73.
[12]Danik SB, Liu F, Zhang J, Suk HJ, Morley GE, Fishman GI, et al. Modulation of cardiac gap junction expression and arrhythmic susceptibility, Circ Res 2004, 95:1035-1041.
[13]Deborch L.Lerner, Kathryn A.Yanada, Richard B.Schuessler, Jeffrey E.Saffitz. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in CX43 deficient mice. Circulation,2000,101:547-552.
[14]Yao JA, Gutstein DE, Liu F, et al. Cell coupling between ventricular myocyte pairs from connexin43-deficient murine hearts.Circulation Research,2003,93: 736-743.
[15]Roell W, Lewalter T, Sasse P, et al. Engraftment of connexin43-expressing cells prevents post-infarct arrhythmia. Nature,2007,450:819-823.
[16]Shigeto Kanno, Attila Kovacs, Kathryn A. Yamada,et al. Saffitz.Connexin43 as a determinant of myocardial infarct size following coronary occlusion in mice.J.Am.Coll.Cardiol,2003,41:681-686.
[17]Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J,2006,397:1-14.
[18]范书英,柯元楠,曾玉杰等.不同p受体阻滞剂对大鼠心肌间隙连接结构作用的对比研究.中华心血管病杂志,2007,35(2)：182-186.
[19]Huazhi Wen, Hong Jiang, Zhibing Lu, et al. Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. Tohoku J.Exp.Med,2009,218:121-127.
[20]范书英,柯元楠,曾玉杰等.卡维地洛对大鼠心肌间隙连接通讯的影响及作用机制研究.中华心血管病杂志,2005,33(12)：1141-1145.
[21]Moreno AP, Lau AF. Gap junction channel gating modulated through protein phosphorylation.Prog Bioph ys Mol Biol,2007,94:106-118.
[22]Solan JL, Lamp e PD. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim Biophys Acta,2005,1711:154-163.
[23]Schulz R, Heusch G. Connexin43 and ischemic preconditioning. Cardiovasc Res,2004,62:335-344.
[24]Michael A. Beardslee, Deborah L. Lerner, Peter N. Tadros, et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circulation Research,2000, 87:656-662
[25]Mark S. Turner, Guy A. Haywood, Peter Andreka, et al. Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels. Circulation Research,2004,95:726-733.
[26]Xiaoyong Bao, Luis Reuss, Guillermo A. Altenberg. Regulation of purified and reconstituted connexin 43 hemichannels by protein kinase C-mediated phosphorylation of Serine 368.Journal of Biological Chemistry,2004,279 (19):20058-20066.
[27]Paul D. Lampe, EriCa M. TenBroek, Janis M. Burt, et al. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. The Journal of Cell Biology,2000,19(7):1503-1512.
[28]Jose F. Ek-Vitorin, Timothy J. King, Nathanael S. Heyman, et al. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circulation Research,2006,98:1498-1505
[29]Bradley W. Doble, Peipei Ping, Elissavet Kardami. The ε subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation.Circulation Research,2000,86:293-301.
[30]Michael P. O'Quinn, Joseph A. Palatinus, Brett S. Harris, et al. A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circulation Research,2011, 108:704-715.
[31]Tetsuji Miura, Yoshito Ohnuma, Atsushi Kuno, et al. Protective role of gap junctions in preconditioning against myocardial infarction. Am J Physiol Heart Circ Physiol,2004,286:H214-H221.
[2]戴梅,张大炜,旭升等.魏执真辨治快速性心律失常的临床经验.北京中医药,2011,30(5)：343-345.
[3]杨洁,张文高.张文高治疗心律失常三法.辽宁中医杂志,2011,38(9)：1887-1889.
[4]梁逸强,周端.周端教授辨治心律失常的经验撷萃.云南中医学院学报,2011,34(6)：38-40.
[5]祁慧霞,牛天福,李娟.中医治疗室性期前收缩的研究进展.中西医结合心脑血管病杂志,2011,9(12)：1501-1502.
[6]尹克春,林敏婷,刘淑娟等.冠心病室性心律失常的中医证候分布规律临床观察.辽宁中医杂志,2008,35(4)：536-538.
[7]杨涛.裴正学教授治疗心律失常的经验.中国社区医师·医学专业,2011,13(25)：150-151.
[8]周仲瑛.中医内科学.中国中医药出版社,北京：2003年.
[9]徐贵成.心律失常治疗的中医优势.中国医院用药评价与分析,2011,11(9)：770
[10]丁碧云.徐经世治疗心律失常证治规律探讨.中西医结合心脑血管病杂志,2011,9(1)：112-114
[11]袁灿宇,袁智宇,袁晓宇.袁海波教授治疗冠心病心律失常经验探讨.中医学报,2010,25(5)：874-875.
[12]李庆海,李庆玉,史海霞.心悸宁丸治疗快速型心律失常的临床观察.中医学报,2009,24(6)：44-45.
[13]张洁,刘建东,张雅玲等.悸安冲剂治疗冠心病心律失常疗效观察.上海中医药杂志,2005,39(8)：13-14.
[14]杨淑媛,黄永生.温阳止悸饮治疗冠心病劳累性稳定型心绞痛室性期前收缩阳(气)虚气滞候的临床观察.吉林中医药,2007,27(9)：13-14.
[15]李芳,李霞,丁瑜.炙甘草汤和桃红四物汤加味治疗冠心病室性早搏疗效观察.辽宁中医药大学学报,2010,12(8)：146-147.
[16]陈国通,邹襄谷,陈永忠.炙甘草汤联合心律平治疗气阴两虚型冠心病并发室性心律失常50例临床观察.福建中医药,2010,41(3)：11-12.
[17]王东琦,苏显明,崔长琮.J波和J波综合征.中国心脏起搏与心电生理杂志,2008,22(1)：4
[18]郭继鸿.猝死高危预警的新指标：缺血性J波.中国心脏起搏与心电生理杂志,2008,22(1)：6
[19]郭继鸿.抗心律失常中药的应用优势.中国循证心血管医学杂志,2010,2(4)：198-201.
[20]刘元伟,郭继鸿,张萍等.稳心颗粒甘松提取物对大鼠心室肌细胞钠电流和
瞬时外向钾电流激活动力学的影响.中国心脏起搏与心电生理杂志,2009,23(6)：533-535.
[21]卢志红,吴旭斌,刘伶等.稳心颗粒对急性冠脉综合征合并心律失常影响的多中心临床研究.实用临床医药杂志,2010,14(1)：59-62.
[22]任乃照,张建中.稳心颗粒治疗冠心病期前收缩116例.中西医结合心脑血管病杂志,2009,7(5)：603-604.
[23]刘建和,莫观海,唐路等.稳心颗粒治疗冠心病室性期前收缩的临床研究.中西医结合心脑血管病杂志,2007,5(10)：922-924.
[24]王万华,徐显华,钟景页等.稳心颗粒治疗老年人冠心病室性期前收缩的临床疗效.中西医结合心脑血管病杂志,2006,4(10)：847-848.
[25]徐涛,张煜,王昊等.参松养心胶囊对兔跨室壁复极离散度的影响.疑难病杂志,2011,10(12)：916-918.
[26]孙莉萍,李宁,张树林等.参松养心胶囊对Hhcn4起搏电流通道的影响.中西医结合心脑血管病杂志,2010,8(5)：530-531
[27]吴以岭,谷春华,高学东等.参松养心胶囊治疗冠心病室性早搏的随机双盲多中心临床研究.疑难病杂志,2007,6(8)：449-452.
[28]杨天伦,吴声滨,谢启应等.参松养心胶囊治疗冠心病室性早搏疗效及对生活质量影响的对比研究.中国中医基础医学杂志,2009,15(12)：932-935.
[29]胡有志,石杰,向楠等.参松养心胶囊治疗冠心病室性早搏的临床研究(附气阴两虚、心络瘀阻型心悸病例20例).中西医结合心脑血管病杂志,2005,3(9)：760-762.
[30]陈金国,王东平,陶春明等.参松养心胶囊联合通心络胶囊治疗冠心病心力衰竭伴室性早搏的临床研究.疑难病杂志,2008,7(4)：195-197.
[31]刘玉梅,周宇宏,单宏丽等.延胡索乙素对豚鼠单个心室肌细胞钾离子通道的影响[J].中国药理学通报,2005,21(5)：599-601.
[32]唐其柱,黄峥嵘,史锡腾等.甘松提取物对家兔心室肌细胞钠、钙通道的影响.中华心血管病杂志,2004,32(增刊)：267.
[33]张婉,潘振伟,冯铁明等.苦参碱对缺血性心室肌细胞快速延迟整流钾电流的作用.中国药理学通报,2008,24(3)：322-326.
[34]SHAN Hong-li,YANG Bao-feng,ZHOU Yu-hong,et al.Effects of matrine on acontine-induced electrophysiological changes in rat ventricular myocytes. Journal of Chinese Pharmaceutical Science,2004,13(3):193-198
[35]郭治彬,付金国,赵勇等.氧化苦参碱对冠心病患者心律失常及心率变异性的影响.中国中西医结合杂志,2006,26(4)：311-315.
[1]Uemura K, Ueyama T, Shintani-Ishida K, et al. An autopsy report on four sudden cardiac death cases by immobilization.Int Med J,2008,15:301-305.
[2]Tsuchida M, Kawashiri MA, Teramoto R, et al. Impact of severe earthquake on the occurrence of acute coronary syndrome and stroke in a rural area of Japan. Circ J,2009,73:1243-1247.
[3]Kana Unuma, Kaori Shintani-Ishida, Kensuke Tsushima, et al. Connexin-43 redistribution and gap junction activation during forced restraint protects against sudden arrhythmic death in rats. Circ J,2010,74:1087-1095.
[4]De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res,2004,61:208-217.
[5]Giilistan Mese, Gabriele Richard, Thomas W. White. Gap Junctions:basic structure and function.Journal of Investigative Dermatology,2007,127:2516-2524.
[6]Laird DW.Life cycle of connexins in health and disease. Biochem J,2006,394: 527-543
[7]Gaietta G, Deerinck TJ, Adams SR, et al. Multicolor and electron microscopic imaging of connexin trafficking. Science,2002,296:503-507
[8]Evans WH, De VE, Leybaert L. The gap junction cellular internet:connexin hemichannels enter the signalling limelight. Bio chem J,2006,397:1-14
[9]Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res,2004,62:228-232.
[10]Van Veen TAB, Van Rijen HVM, Opthof T. Cardiac gap junction channels: modulation of expression and channel properties.Cardio Vasc Res,2001,51:217-229.
[11]Boengler K, Dodoni G, Rodriguez-Sinovas A, et al. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardio Vase Res,2005,67:234-244.
[12]Goldberg GS, Valiunas V, Brink PR. Selective permeability of gap junction channels. Biochim Biophys Acta,2004,1662:96-101
[13]Severs NJ, Coppen SR, Dupont E, et al. Gap junction alterations in human cardiac disease. Cardiovasc Res,2004,62:368-377.
[14]Severs NJ, Dupont E, Thomas N, et al. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol,2006,42:228-242.
[15]Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardio vase Res,2004,62:228-232.
[16]Saez JC, Berthoud VM, Branes MC, et al. Plasma membrane channels formed by connexins:their regulation and functions. Physiol. Rev,2003,83:1359-1400.
[17]Joell L. Solan, Paul D. Lampc. Key connexin 43 phosphorylation events regulate the gap junction life cycle. J Membrane Biol,2007,217:35-41
[18]Delmar M, Coombs W, Sorgen P, et al. Structural bases for the chemical regulation of connexin43 channels. Cardiovasc Res,2004,62:268-275.
[19]Joell L.SOLAN, Paul D.LAMPE.Connexin43 phosphorylation:structural changes and biological effects.Biochem. J,2009,419:261-272.
[20]TenBroek EM, Lampe PD, Solan JL, et al. Ser364 of connexin43 and the upregulation of gap junction assembly by cAMP.J Cell Biol,2001,155:1307-1318.
[21]Thomas M. Bodenstine, Kedar S. Vaidya, Aimen Ismail, et al. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.Cancer Res,2010,70:10002-10011.
[22]Keiichiro YOGO, Takuya OGAWA, Motofusa AKIYAMA, et al. PKA implicated in the phosphorylation of CX43 induced by stimulation with FSH in rat granulosa cells. J. Reprod.Dev,2006,52(3):321-328.
[23]Xiaoyong Bao, Luis Reuss, Guillermo A. Altenberg. Regulation of purified and reconstituted connexin 43 hemichannels by protein kinase C-mediated phosphorylation of serine 368.Journal of Biological Chemistry,2004,279 (19): 20058-20066.
[24]Jose F. Ek-Vitorin, Timothy J. King, Nathanael S. Heyman, et al. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circulation Research,2006,98:1498-1505
[25]Paul D. Lampe, Erica M. TenBroek, Janis M. Burt, et al. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. The Journal of Cell Biology,2000,19(7):1503-1512.
[26]Bradley W. Doble, Peipei Ping, Elissavet Kardami. The ε subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation.Circulation Research,2000,86:293-301.
[27]Edgar Rivedal, Hanne Opsahl. Role of PKC and MAP kinase in EGF-and TPA-induced connexin43 phosphorylation and inhibition of gap junction intercellular communication in rat liver epithelial cells.Carcinogenesis,2001,22 (9):1543-1550.
[28]Cottrell GT, Lin R, Warn-Cramer BJ, et al. Mechanism of v-Src and mitogen activated protein kinase-induced reduction of gap junction communication.American Journal of Physiology,2003,284:C511-C520.
[29]G. Trevor Cottrell, Rui Lin, Bonnie J. et al. Mechanism of v-Src and mitogen-activated protein kinase-induced reduction of gap junction communication. Am J Physiol Cell Physiol,2003,284:511-520.
[30]Solveig Sirnes, Ane Kjenseth, Edward Leithe, Edgar Rivedal. Interplay between PKC and the MAP kinase pathway in connexin43 phosphorylation and inhibition of gap junction intercellular communication.Biochemical and Biophysical Research Communications,2009,382(1):41-45.
[31]Stefan D. Gross, Calvin Simerly, Gerald Schatten, Richard A. Anderson. A casein kinase Ⅰ isoform is required for proper cell cycle progression in the fertilized mouse oocyte. J. Cell Sci,1997,110:3083-3090
[32]Jiangyu Zhu, Futoshi Shibasaki, Roydon Price, et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase Ⅰ and MEKK1. Cell Press, 1998,95(5):851-861.
[33]Jochen Walter, Regina Fluhrer, Bianka Hartung, et al. Phosphorylation regulates intracellular trafficking of β-Secretase. J. Biol. Chem,2001,276 (18):14634-14641.
[34]Renee M. McKay, John M. Peters, Jonathan M. Graff. The casein kinase Ⅰ family in wnt signaling.Developmental Biology,2001,235(2):388-396.
[35]Cynthia D. Cooper, Paul D. Lampe. Casein kinase 1 regulates connexin-43 gap junction assembly, J.Biol.Chem,2002,277(47):44962-44968.
[36]Madhuri Pahujaa, Michael Anikin, Gary S. Goldberg. Phosphorylation of connexin43 induced by Src:regulation of gap junctional communication between transformed cells. Experimental cell research,2007,313(20):4083-4090.
[37]Rui Lin, Bonnie J. Warn-Cramer, Wendy E. Kurata, Alan F. Lau.v-Src phosphorylation of connexin 43 on Tyr247 and Tyr265 disrupts gap junctional communication. J.CELL.Biol,2001,154(4):815-827.
[38]Ben N. G. Giepmans, Trudi Hengeveld, Friso R. Postma, Wouter H. Moolenaar.Interaction of c-Src with gap junction protein connexin-43.J.Biol. Chemi,2001,276 (11):8544-8549.
[39]Teunissen BE, Bierhuizen MF. Transcriptional control of myocardial connexins.Cardiovasc Res,2004,62:246-255.
[40]Saffitz JE, Kleber AG. Effects of mechanical forces and mediators of hypertrophy on remodeling of gap junctions in the heart.Circ Res,2004,94:585-591.
[41]Oxford EM, Musa H, Maass K, et al. Connexin43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells.Circ Res,2007,101:703-711.
[42]Bruce AF, Rothery S, Dupont E, et al. Gap junction remodeling in human heart failure is associated with increased interaction of connexin43 with ZO-1. Cardiovasc Res,2008,77:757-765.
[43]Li J, Patel VV, Radice GL. Dysregulation of cell adhesion proteins and cardiac arrhythmogenesis. Clin Med Res,2006,4:42-52.
[44]Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res,2002,54:361-79.
[45]Ai Z, Fischer A, Spray DC, Brown AM, Fishman GI.Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Invest,2000,105:161-171
[46]Chen XY, Bonne S, Hatzfeld M, van Roy F, Green KJ.Protein binding and functional characterization of plakophilin evidence for its diverse roles in desmosomes and β-catenin signaling. J Biol Chem,2002,277:10512-10522.
[47]Nicholas J. Severs, Alexandra F. Bruce, Emmanuel Dupont, Stephen Rothery.Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovascular Research,2008,80:9-19.
[48]Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov,2006,5:1034-1049
[49]YU zhibin, SHENG Juanjuan.Remodeling of cardic gap junctions and arrhythmias.Acta Physiologica Sinica,2011,63(6):586-592.
[50]N.RIBULOVA, V. KNEZL, E.OKRUHLICOVA, J.SLEZAK. Myocardial gap junctions:targets for novel approaches in the prevention of life-threating cardiac arrhythmias. Physiol. Res,2008,57(Suppl.2):1-13.
[51]Gutstein DE, Morley GE, Vaidya D, et al. Heterogeneous expression of gap junction channels in the heart leads to conduction defects and ventricular dysfunction.Circulation,2001,104:1194-1199.
[52]Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in CX43-deficient mice.Circulation,2000,101:547-52.
[53]Danik SB, Liu F, Zhang J, et al. Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res,2004,95:1035-1041.
[54]Poelzing S, Rosenbaum DS. Altered connexin43 expression produces arrhythmia substrate in heart failure.Am J Physiol Heart Circ Physiol,2004, 287:H1762-H1770.
[55]Severs NJ, Bruce AF, Dupont E, Rothery S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res,2008,80:9-19.
[56]Matsushita T, Oyamada M, Fujimoto K, et al. Remodeling of cell-cell and cell-extracellular matrix interactions at the border zone of rat myocardial infarction.Circ Res,1999,85:1046-1055.
[57]Lampe PD, Cooper CD, King TJ, Burt JM. Analysis of connexin43 phos-phorylated at S325, S328 and S330 in normoxic and ischemic heart.J Cell Sci, 2006,119:3435-3442.
[58]Gutstein DE, Morley GE, Tamaddon H, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43.Circ Res,2001,88:333-39.
[59]Danik SB, Rosner G, Lader J, et al. Electrical remodeling contributes to complex tachyarrhythmias in connexin43-deficient mouse hearts. FASEB J,2008, 22:1204-1212.
[60]Kaprielian RR, Gunning M, Dupont E, et al, Underwood R, et al. Down-regulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation,1998,97:651-660.
[61]Yao JA, Hussain W, Patel P, et al. Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts.Circ Res,2003, 92:437-443.
[62]Akar FG, Nass RD, Hahn S, et al. Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure.Am J Physiol Heart Circ Physiol,2007,293:H1223-H1230.
[63]Uzzaman M, Honjo H, Takagishi Y, et al.Remodeling of gap-junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension.Circ Res,2000,86:871-878.
[64]Peters NS, Severs NJ, Coromilas J, Wit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation,1997,95:988-996.
[65]Sepp R, Severs NJ, Gourdie RG.Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart,1996,76:412-17.
[66]Papp R, G onczi M, Kovacs M, et al. Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischemic preconditioning. Cardiovasc Res,2007,74(3):396-405
[67]Axelsen LN, Stahlhut M, Mohammed S, et al. Identification of ischemia-regulated phosphorylation sites in connexin43:A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Mol Cell Cardiol,2006,40 (6):790-798.
[68]Michael P. O'Quinn, Joseph A. Palatinus, Brett S. Harris, et al. A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circulation Research,2011, 108:704-715.
[69]Tetsuji Miura, Yoshito Ohnuma, Atsushi Kuno, et al. Protective role of gap junctions in preconditioning against myocardial infarction. Am J Physiol Heart Circ Physiol,2004,286:H214-H221.
[70]Shahriar Iravanian, Ali A.Sovari, Harvey A.Lardin, et al. Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43. J Mol Med (Berl),2011,89(7):677-687.
[71]Benjamin F. Remo, Jiaxiang Qu, Frank M. Volpicelli, et al. Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent arrhythmias. Circulation Research,2011,108:1459-1466
[72]Miura T, Ohnuma Y, Kuno A, et al. Protective role of gap junctions in preconditioning against myocardial infarction. Am. J. Physiol Heart Circ Physiol, 2004,55(1):214-2211
[73]Wattamon Srisakuldee, Maya M. Jeyaraman, Barbara E. Nickel, et al. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovascular Research,2009,83:672-681.
[1]马胜兴,陈可冀,王荣金.延胡索碱治疗过早搏动的临床研究[J].中华心血管病杂志,1983,11(1)：6-9.
[2]马胜兴,陈可冀,马玉玲,等.延胡索抗心律失常作用的初步实验[J].中药通报,1985,10(11)：41-42.
[3]汪大金,毛焕元,黄从新.植物性钙拮抗剂颅痛定的抗心律失常临床疗效及其电生理作用[J].同济医科大学学报,1993,22(5)：322-324.
[4]汪大金,毛焕元,黄从新,等.罗通定在预激综合征病人中的临床电生理作用[J].中华心血管病杂志,1993,21(5)：286.
[5]唐召力.颅痛定治疗预激综合征所合并的快速室上性心律失常[J].急诊医学,1999,8(6)：399-400.
[6]韩凤波.硫酸罗通定注射液治疗快速室上性心律失常[J].天津药学,2002,14(1)：44-45.
[7]姚伟星,夏国瑾,曾维忠,等.7-氯苄基四氢巴马汀的抗心律失常作用[J].中国药理学与毒理学杂志,1995,9(3)：220-223.
[8]闵清,吴基良,罗德生,等.7-氯苄基四氢巴马汀对L2甲状腺素诱发大鼠心肌肥厚及左心室肌原纤维Na+-K+-ATPase活力的影响[J].咸宁学院学报(医学版),2004,18(6)：385-387.
[9]闵清,白育庭,吴基良,等.7-氯苄基四氢巴马汀对豚鼠离体心房的作用[J].咸宁学院学报,2000,14(2)：97-99.
[10]张桂清,曾秋棠,曹林生,等.四氢巴马汀对氯化铯诱发家兔在体心脏早后除极和触发性室性心律失常作用的研究[J].中华心律失常学杂志,2000,4(3)：208.
[11]曾秋棠,张桂清,曹林生,等.四氢巴马汀抗触发性室性心律失常作用机制的研究[J].中华内科杂志,2000,39(10)：667-669.
[12]杨宝峰,姚伟星,夏国瑾,等.7-溴化乙氧苯四氢巴马汀的抗心律失常作用[J].中国药理学与毒理学杂志,1990,4(2)：95-98.
[13]杨宝峰,陈庆文,张永春,等.7-溴化乙氧苯四氢巴马汀抑制外向钾电流和尾电流[J].中国药理学通报,1994,10(5)：352-354.
[14]杨宝峰,宗贤刚,王刚,等.7-溴化乙氧苯四氢巴马汀抗心律失常作用的机理[J].药学学报,1990,25(7)：481-484.
[15]曾维忠,夏国瑾,姚伟星,等.苄基四氢巴马汀对心肌动作电位及浦氏纤维跨膜钾、钙离子流的影响[J].中国药理学报,1990,11(4)：314-317.
[16]刘玉梅,周宇宏,单宏丽,等.延胡索乙素对豚鼠单个心室肌细胞钾离子通道 的影响[J].中国药理学通报,2005,21(5)：599-601.
[17]Miake J, Marban E, Nuss HB. Functional role of inward rectifier current in heart probed by Kir2.1 over-expression and dominant-negative suppression.J Clin Invest,2003,111(10):1529-1536.
[18]程龙献,毛焕元,戴水平,等.颅痛定对单个豚鼠心室肌细胞膜钙通道电流的影响[J].临床心血管病杂志,1995,11(3)：170-172.
[19]赵听,汤浩,王亚杰,等.脱氢紫堇碱对正常和低氧豚鼠心肌细胞内钙的影响[J].中国应用生理学杂志,2003,19(3)：222-225.
[20]黄亚莉,陆彤,蒋文平.内皮素对豚鼠心室肌细胞触发电活动的影响[J].中华心血管病杂志,1995,23(5)：381-383.
[21]马建群,毛焕元,曹林生,等.颅痛定对心肌缺血-再灌注性室性心律失常及血浆内皮素-1浓度的影响[J].中国危重病急救医学,1993,10(1)：7-9.
[22]马建群,毛焕元,曹林生,等.颅痛定对心肌缺血再灌注性室性心律失常及血浆去甲肾上腺素浓度的影响[J].中国实用内科杂志,2002,22(8)：485-486.
[23]汪永孝,郑云敏,谭月华.四氢巴马汀抗缺血再灌注心律失常的作用及其机理[J].中国药理学通报,1993,9(5)：358-361.
[24]闵清,白育庭,吴基良,等.罗通定对大鼠心肌缺血的保护作用[J].医药导报,2001,20(9)：554-555.
[25]闵清,白育庭,舒思洁.四氢巴马汀对大鼠心肌缺血再灌注损伤的保护作用[J].中国误诊学杂志,2007,7(23)：5462-5464.
[1]国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组报告缺血性心脏病的命名及诊断标准.中华心备管病杂志,1981,9(1)：75-76.
[2]陈灏珠.实用内科学[M].第13版.人民卫生出版社,北京：2009：397-1400.
[3]郑筱萸.中药新药临床研究指导原则.北京：中国医药科技出社,2002：69-73.
[4]邓可刚,何庆.循证医学证据的检索与利用(第2版)[M].北京：人民卫生出版社,2008,186.
[5]李博,循证检索实例(见聂绍平主编《医学信息搜集的途径和方法》第25章循证医学专业数据库)[M],人民卫生出版社,北京：2008,558.
[6]Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized clinical trials:is blinding necessary? Control Clin rials,1996,17:1-12.
[7]胡有志,石杰,向楠等.参松养心胶囊治疗冠心病室性早搏的临床研究：附气阴两虚、心络瘀阻型心悸病例20例.中西医结合心脑血管病杂志,2005,3(9)：760-762.
[8]吴以岭,谷春华,高学东等.参松养心胶囊治疗冠心病室性早搏的随机双盲多中心临床研究.疑难病杂志,2007,6(8)：449-452
[9]徐贵成,霍保民,吴以岭等.参松养心胶囊治疗冠心病室性早搏随机双盲、阳性药对照、多中心临床研究.中国中医基础医学杂,2003,9(3)：37-40
[10]刘建和,易刚强,程丑夫.柴胡三参汤治疗冠心病室性期前收缩临床研究.中国中医药信息杂志,2005,12(11)：13-15
[11]罗庆华.定悸稳心汤治疗冠心病室性期前收缩的临床研究.中国医药导报,2007,4(32)：77-78
[12]张琼,周明学,黄永生等.复律保心平口服液治疗冠心病室性早搏的初步临床观察.中国中西医结合杂志,2008,28(6)：509-512
[13]沈安明,谢轶群,吕军.健心胶囊治疗冠心病室性早搏临床观察.实用中西医结合临床,2008,8(6)：11-12
[14]李珂,孙兰军,高克俭等.通脉养心丸治疗冠心病室性早搏(气阴两虚证)多中心临床研究.中西医结合心脑血管病杂志,2010,8(4)：401-403
[15]杨靖,何劲松,杨小英.稳心颗粒合用胺碘酮治疗冠心病室性早搏临床观察.广西中医学院学报,2005,8(3)：18-20
[16]刘建和,莫观海,唐路等.稳心颗粒治疗冠心病室性期前收缩的临床研究.中西医结合心脑血管病杂志,2007,5(10)：922-924
[17]沈红权,黄秀英,曾帼英等.心复平治疗冠心病合并频繁室性早搏的临床研 究.中华临床杂志,2005,1(1)：13-14
[18]李玉峰,鲁卫星.心脉安片治疗冠心病室性早搏40例临床观察.北京中医药大学学报,2003,26(3)：67-69.
[19]李佳,刘淑荣.炙甘草汤加味治疗冠心病室性早搏的临床研究.2009年会议集：仲景医学求真(续三)：434-442.
[20]凌静.中西医结合治疗冠心病室性早搏45例临床观察.中医药导,.2007,13(2)：28-29.
[1]中华医学会心血管病学分会.急性心肌梗死诊断和治疗指南.中华心血管病杂志,2001,29(12)：710-725.
[2]中华医学会心血管病学分会,中国生物医学工程学会心脏起搏与心电生理分会,中华心血管病杂志编辑委员会,中国心脏起搏与心电生理杂志编辑委员会.室上性快速心律失常治疗指南.中华心血管病杂志,2005,33(1)：2-15
[3]陈新.黄宛临床心电图学(第六版)[M].北京：人民卫生出版社.2009,235-358.
[4]中国中西医结合学会心血管病专业委员会.冠心病中医辨证标准.中国中西医结合杂志,1991,11(5)：257.
[5]Douglas P. Zipes, A. John Camm, Martin Borggrefe, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary:A report of the American College of Cardiology/AmeriCan Heart Association task force and the European Society of Cardiology Committee for practice guidelines (Writing Committee to
develop guidelines for management o f patients with ventricular arrhythmias and the prevention of sudden cardiac death) Developed in collaboration with the
European Heart Rhythm Association and the Heart Rhythm Society. European Heart Journal,2006,27:2099-2140.
[6]吴立群,戚文航.心力衰竭时的心律失常与猝死.内科急危重症杂志,2005,11(6)：249-252
[7]马胜兴,陈可冀,王荣金.延胡索碱治疗过早搏动的临床研究.中华心血管病杂志,1983,11：6-10.
[8]马胜兴,陈可冀,马玉玲,包晓峰.延胡索抗心律失常作用的初步实验.中药通报,1985,11：41-42.
[9]刘剑刚,刘立新,马晓斌,等.延胡索碱注射液对大鼠实验性急性心肌梗塞和红细胞流变性的作用.中药新药与临床药理,2000,2：76-79.
[10]Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing:summary article:a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to update the 1997 exercise testing guidelines). J Am Coll Cardiol, 2002,40:1531-1540.
[11]Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations.N Engl J Med, 2000,343:826-833.
[12]杨洁,张文高.张文高治疗心律失常三法.辽宁中医杂志,2011,38(9)：1887-1889.
[13]周仲瑛.中医内科学.中国中医药出版社,北京：2003.
[14]徐贵成.心律失常治疗的中医优势.中国医院用药评价与分析,2011,11(9)：770
[15]张京春,谢元华.陈可冀院士辨治冠心病医案的数据挖掘.世界中西医结合杂志,2008,3(1)：4-5,7.
[16]Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, et al.2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/Non ST-elevation myocardial infarction:A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation,2011,123:1-154.
[17]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南.中华心血管病杂志,2007,35(4)：295-304.
[18]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志,2010,38(8)：675-690.
[19]Poole JE, Bardy GH, Sudden Cardiac Death. In:Zipes DP, Jalife J, eds. Cardiac Electrophysiology:From cell to bedside.3rd edn. Philadelphia, PA:W.B. Saunders Company,2000,615-640.
[20]Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation,2000,102:724-747.
[21]ECC Committee, Subcommittee and task forces of the American Heart Association.2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care.Circulation,2005,112:Ⅳ1-Ⅳ203.
[1]邵博一.稳心颗粒联合阿托伐他汀治疗缺血性心律失常的临床研究.中国实用医药.2007,2(4)：69-70.
[2]苏显明,王东琦,于忠祥等.急性心肌缺血犬心肌细胞瞬时外向钾电流和跨壁复极离散度变化致心律失常机制研究.临床心血管病杂志,2006,22(3)：140-144.
[3]施慧,龙子江,王靓等.宁心律康颗粒抗急性心肌缺血诱发心律失常的实验研究.中成药.2011,33(6)：1044-1046.
[4]陈修,陈维州,曾贵云.心血管药理[M].3版,北京：人民卫生出版社.2002：425-431.
[5]De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res.2004,61:208-217.
[6]李荣,吴伟,李文等.延胡索碱预处理对大鼠心肌缺血再灌注心律失常的干预作用.中药新药与临床药理.2010,21(3)：237-240.
[7]刘剑刚,刘立新,马晓斌等.延胡索碱注射液对大鼠实验性急性心肌梗死和红细胞流变性的作用.中药新药与临床药理.2000,11(2)：76-79.
[1]姚泰.生理学.人民卫生出版社,北京,2006：28-29.
[2]杨孝芳,刘小雨,习君萍.心肌缺血再灌注损伤的钙信号调节.中国临床康复,2006,10(44)：93-95.
[3]Zhao SX, Lee LM, Nearing BD, et al.Suppression of Calcium-induced repolarization heterogeneity as a mechanism of nitroglycerin's antiarrhythmic action.J Cardiovasc Pharmacol,2006,48:22-29.
[4]Liu J, Tian J, Haas M, et al. Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na+and Ca2+ concentrations.J Biol Chem,2000,275:27838-27844.
[5]Xie Z, Cai T. Na+-K+-ATPase-mediated signal transduction:from protein interaction to cellular function.Mol Interv,2003,3:157-168.
[6]Xu K.Y. Activation of Na+-K+-ATPase. Biochem Biophys Res Commun,2005, 338:1669-1677.
[7]Lee DI, Klein MG, Zhu W, et al. Activation of Na+-K+-ATPase modulates cardiac L-type Ca2+channel function. Mol Pharmacol,2009,75:774-81.
[8]Jin Zheng, Xiuxian Koh, Fei Hua, et al. Cardioprotection induced by Na+/K+-ATPase activation involves extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/Akt pathway. Cardiovascular Research,2011,89:51-59.
[9]P. KAPLAN, M. MATEJOVI COVA, P. HERIJGERS, et al. Lack of the effect of superoxide dismutase and catalase on Na+-K+-ATPase activity in stunned rabbit hearts.Physiol.Res(Suppl.2),2008,57:S61-S66.
[10]Stefanon, J.R. Cade, A.A. Fernandes, et al. Ventricular performance and Na+-K+-ATPase activity are reduced early and late after myocardial infarction in rats.Brazlilian Journal of MediCal and BiologiCal Research,2009,42:902-911.
[11]Javier Inserte, David Garcia-Dorado, Victor Hernando, et al. Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circulation Research,2005, 97:465-473.
[12]Singh RB, Dhalla NS.Ischemia-reperfusion-induced changes in sarcolemmal Na+/K+-ATPase are due to the activation of calpain in the heart. Can J Physiol Pharmacol,2010,88(3):388-397.
[13]Javier Inserte, David Garcia-Dorado, Victor Hernando, et al. Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion. Cardiovascular Research,2006,70:364-373.
[14]Larissa Lipskaia, Elie R Chemaly, Lahouaria Hadri, et al. Sarcoplasmic reticulum Ca2+ATPase as a therapeutic target for heart failure. Expert Opinion on BiologiCal Therapy Journal,2010,10(1):29-41.
[15]王永亮,范晓燕,刘关省等.心衰心肌细胞肌浆网钙泵对兴奋收缩偶联功能的影响.电子显微学报,2010,29(5)：486-490.
[16]Cho-Kai Wu, Chuen-Den Tseng, Yin-Tsen Huang, et al. Angiotensin II does not influence expression of sarcoplasmic reticulum Ca2+-ATPase in atrial myocytes. Journal of Renin-Angiotensin-Aldosterone System.2009,10(3):121-126.
[17]Hui Sun, Denis Chartier, Normand Leblanc, et al.Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res,2001,49:751-761.
[18]Christian E. Zaugg, Peter T. Buser. When calcium turns arrhythmogenic: intracellular calcium handling during the development of hypertrophy and heart failure. Croatian MediCal Journal,2001,42(1):24-32.
[19]Simon Sedej, Frank R. Heinzel, Stefanie Walther, et al. Na+-dependent SR Ca2+overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovascular Research,2010,87:50-59.
[20]U. Ravens, D. Dobrev.Regulation of sarcoplasmic reticulum Ca2+-ATPase and phospholamban in the failing and nonfailing heart.Cardiovascular Research,2000, 45:245-252.
[21]Przemyslaw Leszek, Malgorzata Szperl, Anna Klisiewicz, et al. Alteration of myocardial sarcoplasmic reticulum Ca2+-ATPase and Na+-Ca2+exchanger expression in human left ventricular volume overload. European Journal of Heart Failure,2007,9:579-586.
[22]Sufen Wang, Jeejabai Radhakrishnan, Iyad M. Ayoub, et al. Limiting sarcolemmal Na+entry during resuscitation from ventricular fibrillation prevents excess mitochondrial Ca2+accumulation and attenuates myocardial injury. J Appl Physiol,2007,103:55-65.
[23]Waldenstrom A, Ronquist G, Aberg AM, et al. Ischaemic preconditioning reduces myocardial calcium overload in coronary-occluded pig hearts shown by continuous in vivo assessment using microdialysis. Clin Physiol Funct Imaging, 2012,32(2):133-138.
[24]O.D. Pedersen, H. Bagger, L. Kober, C. Torp-Pedersen. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction.TRACE study group. Eur Heart J,1999,20:748-754.
[25]W. Haverkamp, H. Gulker, G. Hindricks, et al. Effects of beta-blockade on the incidence of ventricular tachyarrhythmias during acute myocardial ischemia: experimental findings and clinical implications. Basic Res Cardiol,1990,95: 293-303.
[26]G.Olsson, J.Wikstrand, I.Warnold, et al. Metoprolol-induced reduction in postinfarction mortality:pooled results from five double-blind randomized trials. Eur Heart J,1992,13(1):28-32.
[27]John McMurray, Lars Kober, Michele Robertson, et al. Antiarrhythmic effect of Carvedilol after acute myocardial infarction:results of the Carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology,2005,45(4):525-530.
[28]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.p肾上腺素能受体阻滞剂在心血管疾病应用专家共识.中华心血管病杂志,2009,37(3)：195-209.
[29]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志,2010,38(8)：675-690.
[30]李荣,吴伟,李文晞等.延胡索碱预处理对缺血再灌注心肌钙泵及钠钾泵活性的影响.辽宁中医杂志,2010,37(8)：1613-1615.
[1]Severs NJ, Coppen SR, Dupont E, et al. Gap junction alterations in human cardiac disease. Cardiovasc Res,2004,62:368-377.
[2]Severs NJ, Dupont E, Thomas N, et al. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol,2006,42:228-242.
[3]Sawa Kostin, Markus Rieger, Sebastian Dammer, et al. Gap junction remodeling and altered connexin43 expression in the failing human heart. Molecular and Cellular Biochemistry,2003,242:135-144.
[4]David E.Gutstein, Gregory E.Morley, Houman Tamaddon, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circulation Research,2001,83:333-339.
[5]Uemura K, Ueyama T, Shintani-Ishida K, et al.An autopsy report on four sudden cardiac death cases by immobilization.Int Med J,2008,15:301-305.
[6]Tsuchida M, Kawashiri MA, Teramoto R, et al.Impact of severe earthquake on the occurrence of acute coronary syndrome and stroke in a rural area of Japan. Circ J,2009,73:1243-1247.
[7]Kana Unuma, Kaori Shintani-Ishida, Kensuke Tsushima, et al. Connexin-43 redistribution and gap junction activation during forced restraint protects against sudden arrhythmic death in rats. Circ J,2010,74:1087-1095.
[8]Marisol Ruiz-Meana, Antonio Rodri'guez-Sinovas, Alberto Cabestrero, et al. Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischemia-reperfusion injury. Cardiovascular Research,2008,77:325-333.
[9]Nicholas J.Severs, Alexandra F.Bruce, Emmanuel Dupont, Stephen Rothery. Remodeling of gap junctions and connexin expression in diseased myocardium. Cardiovascular Research,2008,80:9-19.
[10]De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res,2004,61:208-217.
[111]Zeevi-Levin N, Barac YD, Reisner Y, et al. Gap junctional remodeling by hypoxia in cultured neonata 1 rat ventricular myocytes.Cardiovasc Res,2005, 66:64-73.
[12]Danik SB, Liu F, Zhang J, Suk HJ, Morley GE, Fishman GI, et al. Modulation of cardiac gap junction expression and arrhythmic susceptibility, Circ Res 2004, 95:1035-1041.
[13]Deborch L.Lerner, Kathryn A.Yanada, Richard B.Schuessler, Jeffrey E.Saffitz. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in CX43 deficient mice. Circulation,2000,101:547-552.
[14]Yao JA, Gutstein DE, Liu F, et al. Cell coupling between ventricular myocyte pairs from connexin43-deficient murine hearts.Circulation Research,2003,93: 736-743.
[15]Roell W, Lewalter T, Sasse P, et al. Engraftment of connexin43-expressing cells prevents post-infarct arrhythmia. Nature,2007,450:819-823.
[16]Shigeto Kanno, Attila Kovacs, Kathryn A. Yamada,et al. Saffitz.Connexin43 as a determinant of myocardial infarct size following coronary occlusion in mice.J.Am.Coll.Cardiol,2003,41:681-686.
[17]Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J,2006,397:1-14.
[18]范书英,柯元楠,曾玉杰等.不同p受体阻滞剂对大鼠心肌间隙连接结构作用的对比研究.中华心血管病杂志,2007,35(2)：182-186.
[19]Huazhi Wen, Hong Jiang, Zhibing Lu, et al. Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. Tohoku J.Exp.Med,2009,218:121-127.
[20]范书英,柯元楠,曾玉杰等.卡维地洛对大鼠心肌间隙连接通讯的影响及作用机制研究.中华心血管病杂志,2005,33(12)：1141-1145.
[21]Moreno AP, Lau AF. Gap junction channel gating modulated through protein phosphorylation.Prog Bioph ys Mol Biol,2007,94:106-118.
[22]Solan JL, Lamp e PD. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim Biophys Acta,2005,1711:154-163.
[23]Schulz R, Heusch G. Connexin43 and ischemic preconditioning. Cardiovasc Res,2004,62:335-344.
[24]Michael A. Beardslee, Deborah L. Lerner, Peter N. Tadros, et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circulation Research,2000, 87:656-662
[25]Mark S. Turner, Guy A. Haywood, Peter Andreka, et al. Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels. Circulation Research,2004,95:726-733.
[26]Xiaoyong Bao, Luis Reuss, Guillermo A. Altenberg. Regulation of purified and reconstituted connexin 43 hemichannels by protein kinase C-mediated phosphorylation of Serine 368.Journal of Biological Chemistry,2004,279 (19):20058-20066.
[27]Paul D. Lampe, EriCa M. TenBroek, Janis M. Burt, et al. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. The Journal of Cell Biology,2000,19(7):1503-1512.
[28]Jose F. Ek-Vitorin, Timothy J. King, Nathanael S. Heyman, et al. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circulation Research,2006,98:1498-1505
[29]Bradley W. Doble, Peipei Ping, Elissavet Kardami. The ε subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation.Circulation Research,2000,86:293-301.
[30]Michael P. O'Quinn, Joseph A. Palatinus, Brett S. Harris, et al. A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circulation Research,2011, 108:704-715.
[31]Tetsuji Miura, Yoshito Ohnuma, Atsushi Kuno, et al. Protective role of gap junctions in preconditioning against myocardial infarction. Am J Physiol Heart Circ Physiol,2004,286:H214-H221.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |